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Abstract 
The strength of health systems predict access to medicines that prevent death from pregnancy 
related complications (essential maternal health medicines). But little is known about the relative 
impact of each health system building block on access. This quantitative cross-sectional study 
applied Ishikawa model to examine the relative effect of health systems governance, facilities, 
service delivery, financing and medicine procurement and distribution (independent variables), 
on availability, affordability and accessibility (dependent variables) of maternal health medicines 
in resource poor settings. Data analyzed was pulled from 37 WHO pharmaceutical country 
profiles and USAID MCHIP survey that assessed national programs for the prevention and 
management of Postpartum hemorrhage and Pre-Eclampsia/Eclampsia. Data analysis included 
bivariate and multivariate logistic regressions. All independent variables, except for quality of 
health services showed statistically significant association with access to maternal health 
medicines and achieved a p-value < .05 in bivariate analysis. Only three predictors however 
explained 27% of the variance (R2 =.266, F(5,162)=13.12, p<.01). The strength of medicine 
procurement and distribution systems significantly predicted access to essential maternal health 
medicines (β= -.41, p<.001), as did robustness of health system financing (β= -.51, p<.001), and 
quality of health facilities (β= -.34, p<.05). Authorities may prioritize investments in quality 
improvement, supply chain strengthening programs, and incentives for private sector financing 
and public-private partnerships for health system strengthening. This study contributes to 
positive social change by identifying key health system considerations that can inform future 
efforts to close geographical gaps in MCH outcomes. 
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Section 1: Foundation of Study and Literature Review 
 
Introduction to the Study 
Postpartum hemorrhage (PPH), pre-eclampsia and eclampsia are three leading causes of 
death for women giving birth around the world. These conditions together account for nearly half 
(41%) of the 289,000 pregnancy-related deaths worldwide (WHO, et al., 2014). They also 
disproportionately affect women in developing countries (Say et al., 2014; WHO, 2014b).  
Oxytocin, misoprostol and magnesium sulfate (herein referred to as essential maternal 
health medicines) are three medicines that prevent and treat these pregnancy-related 
complications. (Fujioka, & Smith, 2011). Yet, they are not readily available to women at urban 
and rural hospitals or clinics in many locations where women give birth (USAID, Landscape 
Analysis: Postpartum Hemorrhage Solutions, unpublished data, 2012).  
Expanding access to essential maternal health medicines would lower maternal death 
rates and improve maternal health (Wagstaff, 2004). In one study, USAID anticipated that if 
oxytocin and misoprostol were available to all women giving birth, they would prevent 41 
million postpartum hemorrhage cases and saved 1.4 million lives annually (USAID, Landscape 
Analysis: Postpartum Hemorrhage Solutions, unpublished data, 2012).  
In recognizing these realities, governments of many nations with support from 
multilateral, bilateral and international non-governmental organization have developed and 
implemented programs to improve access to essential maternal health medicines. But despites 
these efforts, women in resource poor settings still lack adequate access to these medicines 
(Spector, Reisman, Lipsitz, Desai, Gawande, 2013; Hill, 2012).  
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Researchers attribute this to the vertical structure of these programs, and the shrinking 
funding for public health witnessed in recent years (Paina and Peters, 2011). In other words, 
components of the health system that affects access to essential maternal health medicines are 
not adequately accounted for in programs to promote access to these medicines. This is either 
because practitioners perceive medicines as a standalone component of a health system or 
funding to promote access are not able to support implementation of multiple and competing 
programs that facilitate access to these medicines (Paina and Peters, 2011). 
 To address these gaps, some studies have attempted to determine health system 
facilitators and barriers to access to essential maternal health medicines. But these studies were 
limited to single geographies, medicines or health system factor (Smith, 2011; Trans and Bero, 
2015; Bigdeli et al., 2013). Therefore, little is known about the relative impact of each health 
system factor on access to essential maternal health medicines, more so comparatively across 
geographies in resources poor settings. There is a paucity of evidence on the factors that facilitate 
or impede access to essential maternal health medicines in low and middle-income countries. 
Health systems determinant of global access to essential maternal health medicines have not 
sufficiently studies using nationally representative data. 
In this study, I examined the relationship between health systems factors and access to 
essential maternal health medicines to understand the relative impact of select health systems 
factors on women’s access to these medicines in developing countries. This study is unique in 
that it will focus on an under researched area of access to essential maternal health medicines.  
Findings from this study will make an original contribution to understanding how 
pregnant women’s interactions with the health system affect the use of maternal health medicines 
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in low and middle-income countries. For the first time, there will be empirical evidence on the 
determinants of women’s access to essential maternal health medicines from a holistic 
perspective.  
Evidence generated through this research can contribute to efforts that aim to expand 
access to essential maternal health medicines. New knowledge generated can be used to sensitize 
policy makers and maternal health practitioners, regarding the potential effects of their decisions 
and interventions respectively on various aspects of the health systems with regards to access to 
maternal health medicines. The evidence can help policy makers and health managers in 
international agencies and national governments to design relevant, timely and evidence 
informed policies and programs to improve pregnant women’s access to maternal health life-
saving medicines and reduce the number of women dying from pregnancy related causes.  
Finally, with multiple intervention options for improving women’s access to maternal 
health medicines, and shrinking funding for public health programs, the information from this 
study could guide selection of investment priorities and pint to areas of work that foster changes 
in policy and practice and inform maternal health research and program priorities. These could 
contribute to a reduction in global and national maternal mortality ratio – a positive social 
change. 
Main aspects of this section include a background that briefly summarizes the knowledge 
gaps the study will attempt to fill, and why the study is important. This section also presents the 
problem statement and purpose of the study. The nature of the study, research questions and 
hypotheses are included alongside the theoretical framework to guide the study. I also present an 
overview of recent literature related to the scope of the study including a review of the theories 
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that form the basis of this study, and the methodological approaches explored in previous related 
studies. I conclude this section with an explanation of what is known and controversial about the 
variables of interest in this study, and what remains to be studied. Finally, assumptions, scope, 
delimitations, limitations and significance of the study are highlighted  
Problem Statement 
Despite recent decrease in global maternal mortality ratio, approximately 830 women still 
die every day because of complications during pregnancy or childbirth (WHO, 2015). The World 
Health organization (WHO) estimated that by the end of 2015, roughly 303,000 women will 
have died during and following pregnancy and childbirth (WHO, 2015). Postpartum hemorrhage 
(PPH), pre-eclampsia and eclampsia are three leading causes of these deaths. In 2014, these 
conditions, together accounted for nearly half (41 % of the 289,000 pregnancy related deaths that 
occurred worldwide (WHO, et al., 2014). While postpartum hemorrhage (PPH) accounted for 
more than two thirds of cases), hypertensive disorders (pre–eclampsia and eclampsia), sepsis, 
and unsafe abortion accounted for the rest (Say et al., 2014). 
These pregnancy-related complications and resulting maternal deaths are not distributed 
evenly across the globe. Rather, an overwhelming 99% of maternal deaths occur in low income 
countries, with over 50% reported in sub-Saharan Africa and almost one third in South Asia. In 
2015 alone, the maternal mortality ratio in developing countries was 239 per 100 000 live births 
versus 12 per 100 000 live births in developed countries (WHO, 2015). Also, the probability that 
a 15–year–old woman will eventually die from a cause related to Postpartum hemorrhage (PPH), 
pre-eclampsia and eclampsia is much higher for women living in low income countries than for 
those who live in high income countries (1:180 vs 1: 4900). Furthermore, more than half of 
5 
 
 
 
maternal deaths in Africa and Asia occur in fragile and humanitarian settings (WHO, 2015). In 
countries designated as fragile states, the risk of dying from a cause related to Postpartum 
hemorrhage (PPH), pre-eclampsia and eclampsia is 1 in 54; a consequence of breakdowns in 
health systems (WHO, 2015). 
The need for oxytocin, misoprostol, and magnesium sulfate (discussed in earlier section) 
is therefore imminent. It is universal and present wherever deliveries occur: from urban hospitals 
to rural clinics and homes where more than 50 percent of women in developing countries deliver 
their babies (Montagu, Yamey, Visconti, Harding, & Yoong, 2011).  
In other to make medicines universally available and accessible, the World Health 
Assembly sanctioned the notion of essential medicines in 1975, and this has been followed by (1) 
highlight in 2012 by the “United Nations Commission on Life-Saving Commodities for Women 
and Children on the need to improve women’s and children’s health by increasing access to 13 
high-quality, essential health supplies, including oxytocin, misoprostol, and magnesium sulfate” 
- (Kade, & Moore, 2012; p.5). (2). Evidence– informed recommendations by the WHO that 
highlight necessary interventions and medicines needed to improve the health of pregnant 
women and prevent complications that occur during pregnancy and childbirth (WHO, 2011b; 
WHO, 2012; WHO, 2013; WHO, 2012c).  
Despite these high level championed efforts, recent data suggest that poor and vulnerable 
women in Africa and Asia still lack adequate access essential maternal health medicines 
(Spector, Reisman, Lipsitz, Desai, Gawande, 2013; Hill, 2012). Researchers attribute this to gaps 
in the approach that characterize programs that aim to promote access to essential maternal 
health medicines at country levels. According to the literature, the role of medicines is often 
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narrowed down to a health system input, so that approaches to improving access to medicines are 
vertical and isolated rather than all-inclusive - considering other health system constraints that 
hamper access to medicines (Paina and Peters, 2011; Bigdeli et al., 2013; p.2). 
Access to maternal health services (such as essential maternal health medicines) has 
important implications on maternal health and mortality. In other to improve access to essential 
maternal health medicines, there is need to understand and incorporate the full spectrum of the 
health system in research and practice regarding access to maternal health medicines (Paina and 
Peters, 2011; Bigdeli et al., 2013; p.2; (Adam, Ahmad, Bigdeli, Ghaffar, & Røttingen, 2011).  
Some studies have explored access to medicines, but not many consider component of the 
health system in ways that are relevant to the unique characteristics of access to essential 
maternal health medicines (Bigdeli et al., 2012). Many limit health system considerations to the 
health sector. For instance, a recent survey of peer-reviewed publications on access to medicines 
in low and middle-income countries demonstrated that only 27 out of 648 between 2003 and 
2009 reported on broader pharmaceutical policies and reforms in low and middle-income 
countries (Adam, Ahmad, Bigdeli, Ghaffar, & Røttingen, 2011). 
These gaps in empirical evidence demonstrate the need for additional research on access 
to maternal health medicines from a health systems perspective.  
Purpose of Study 
The purpose of the study was to determine the relative impact of health system factors on 
access to essential maternal health medicines in low and middle-income countries. The study 
measured the strength of association between each select health system factor and maternal 
health medicines in low and middle-income countries. Health System factors prioritized in this 
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study were identified based on finding from the literature and the knowledge gap on health 
systems and access to maternal health medicines research. 
Knowledge gained through this study could inform national and subnational level 
maternal health policies and programs that have goals to make better the health of women in low 
and middle-income countries. Finally, the study could inform the design of appropriate policies 
that address specific health system factors that constrain women from accessing and using 
essential maternal health medicines. In this era of declining resources for public health, National 
and local level maternal health programs could use the evidence generated in this study to 
identify health system factors limiting access to and use of maternal health medicines, and 
prioritize programs based on their relative potentials to maximize impact.  
Research Questions and Hypotheses 
The Study had six research questions and corresponding hypotheses: 
Is there a significant association between governance and access to essential maternal 
health medicines in low and middle-income countries?  
Ho1: there is no significant association between governance and access to essential 
maternal health medicines in low and middle-income countries?  
Ha1: there is a significant association between the governance and access to essential 
maternal health medicines in low and middle-income countries?  
Is there a significant association between pharmaceutical supply and access to essential 
maternal health medicines in low and middle-income countries?  
Ho2: there is no significant association between pharmaceutical supply and access to 
essential maternal health medicines in low and middle-income countries?  
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Ha2: there is a significant association between pharmaceutical supply and access to 
essential maternal health medicines in low and middle-income countries?  
Is there a significant association between the quality of health facility and access to 
essential maternal health medicines in low and middle-income countries?  
Ho3: there is no significant association between the quality of health facility and access 
to essential maternal health medicines in low and middle-income countries?  
Ha3: there is a significant association between the quality of health facility and access to 
essential maternal health medicines in low and middle-income countries?  
Is there a significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Ho4: there is no significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Ha4: there is a significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Is there a significant relationship between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Ho5: there is no significant association between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Ha5: there is a significant association between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Theoretical Foundation of Study 
Choice of theory. The Ishikawa diagram – an application theory of the complex adaptive 
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system concept guided implementation of this study. Ishikawa diagram - also known as the 
“fishbone” or “cause and effect” diagram was first developed by Kaoru Ishikawa in 1968 and has 
been vastly utilized in the field of public health as well as the manufacturing industry (Ishikawa, 
1968). The main goal of the Fishbone diagram is to illustrate in a graphical way, the relationship 
between a given outcome and all the factors that influence this outcome, and provide additional 
insight into the behavior of processes (Ishikawa, 1960).  
In the 1960’s and 70s, the Ishikawa diagram was commonly used in the manufacturing 
industry to design products, prevent quality defects, and identify potential factors causing an 
effect or outcome. However, because of its characteristic flexibility and potential for wide 
application, the fishbone diagram has been adapted to consider a variety of outcomes or effect 
scenarios across multiple professions.  
Recently, the diagram has been used extensively as theoretical framework for analysis in 
the health care field – mostly as a continuous quality improvement tool to examine the causes of 
a problem within a healthcare setting. For example, Hartwell and colleagues (2006) used the 
fishbone diagram as an analytic approach to identify sources of medication errors in hospitals.  
Maternal health researchers have also applied the Ishikawa framework to studies related 
to access to essential maternal health medicines – the focus of this study. For example, in 2010, 
Ridge et al. developed, used and proposed the use of this diagram to determine facilitators to the 
availability and rational use of MgSO4 in Zambia. In 2013, Bigdeli et al. also used this diagram 
in their study to highlight health system deterrents to access and use of MgSO4 in Pakistan. In 
2015, Tran and Bero used the fishbone Ishikawa diagram that Ridge et al. developed to assess 
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the barriers and facilitators to quality use of three essential medicines – oxytocin, ergometrine, 
and MgSO4 in seven countries.  
Rationale for choice of framework. It was anticipated that firstly, the Ishikawa diagram 
would allow accounting for various factors that potentially predict access since this study aims to 
predict patterns of access from various sources. The supply chain for pharmaceutical products, 
especially in developing countries, are comprised of highly heterogeneous groups of actors (e.g. 
many types of health care providers, managers, policy-makers, patients, regulators, private 
sector, public sector etc.) intervening at multiple levels through a variety of services and 
functions (Holland, 1992; Anderson and McDaniel, 2000; Plsek, and Wilson, 2001; Tan et al., 
2005; Rickles et al., 2007; Saadah & Knowles, 2000).; (de Savigny & Adam 2009); Keshavarz et 
al., 2010). In other words, the medicine supply chain is woven and nested within the health 
system and interacts with the peculiar behavior of different components of the health system at 
any given time (de Savigny & Adam 2009). Medicines concern systems outside of the health 
system and at international level. 
Secondly, scaling up access to essential medicines for maternal health is more than the 
expansion of coverage of health services. Rather, it can be defined as a set of processes that lead 
to expanded and sustainable coverage of services, and should reflect the open and dynamic 
relationship that exist in a health system (Anderson and McDaniel, 2000; Plsek, & Wilson, 
2001). Scale up should also involve strengthening the capacity of delivery organizations, 
increasing diversity and robustness of funding and management arrangements, and growing the 
system's overall capabilities to add more services or to integrate services (Uvin 1995, 
Subramanian et al., 2010; Tan et al., 2005; Leischow, & Milstein, 2006: Van Wave et al., 
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2010),). The Ishikawa diagram is structured to help explain processes that lead to a given 
outcome and potential factors to promote scale up and improvement – hence it is suitable to this 
study. 
Logical Connection 
In using the Ishikawa diagram to determine predictors of access to essential medicines for 
maternal health, Tran and Bero (2015) proposed that facilitators and barriers to quality use of 
oxytocin, ergometrine, and MgSO4 occur in four levels of a health system: (1). 
Government/Regulatory level (2). Pharmaceutical Level (3). Health Facility Level (4) Health 
professional Level. 
In this cross-sectional study, I built on previous studies, like those of Tran and Bero 
(2015). That applied the Ishikawa framework in maternal health medicines research. This 
framework provided a solid platform for understanding relationship between the independent and 
dependent variables for this study. I advanced this diagram through an iterative process that was 
based on data gotten from each country’s report. 
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Figure 1. Ishikawa diagram showing the multi-dimensional predictors of rational use of oxytocin. 
Source: Tran and Bero, (2015) 
 
Nature of the Study 
A quantitative cross-sectional approach was used to answer the research questions. This 
approach is based on post positivist philosophical assumptions that propose: 1). examining the 
relationships between and among variables is central to answering questions and hypotheses 
through surveys and experiments; 2). reducing concepts to a parsimonious set of variables, 
tightly controlled through design and statistical analysis, provides measures or observations for 
testing a theory (Creswell, 2008). The research questions required quantitative analysis for 
measuring access to maternal health medicines, and the associations between health systems 
factors and access to maternal health services. 
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I carried out a secondary analysis of archived data from a sample of Low and Middle-
income Countries (LMIC). Key inclusion criteria were countries that participated in the second 
USAID Bureau for Global Health's flagship Maternal and Child Health Integrated 
Program (USAID/MCHIP) annual global survey between March to June 2012. These surveys 
assessed progress of national programs in the prevention and management of PPH and PE/E 
(USAID, MCHIP (2011, 2012). 
The independent variables for this study were health-system characteristics that influence 
women’s access to essential maternal health medicines. In this regard, five health system 
domains was assessed: government and regulatory, pharmaceutical supply system, health 
facility, and health service delivery, and data collection/information reporting. For each domain, 
at least two health system characteristics or measures that best represent a domain were analyzed 
(table 1.1).The outcome variable for this study was ‘access to essential maternal health 
medicines’, defined as the availability, affordability and accessibility of Oxytocin, Magnesium 
Sulfate and Misoprostol or Egometrin combined. 
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Table 1 
 
Health System Determinants of Access to Maternal Health Medicines 
Variable Dimension Measures 
 
Government/regulation Medicines approved at national level; 
Availability of Standard Treatment Guidelines; 
Policy provision for AMTSL present. 
Pharmaceutical Supply and Distribution Written public sector procurement policy 
available; Public sector procurement is 
Centralized and decentralized? The 
government supply system department has a 
Central Medical Store at National Level; There 
are national guidelines on Good Distribution 
Practices (GDP) 
Health Facilities and Infrastructures Number of hospital beds per 10,000 
Number of Physicians per 000 pop. 
Service Delivery Pre-service education curricula include 
AMTSL  
Current global management principles for 
PE/E included in in-service training courses 
 
AMTSL included in in-service training 
curricula 
Pre-service education curricula include current 
global management principles for PE/E 
Students assessed for competency in 
performance of AMTSL 
Health providers aware medicine is first–line 
treatment 
Midwife/skilled birth attendants scope of 
practice 
Health Financing Private health expenditure as % of total health 
expenditure (% of total expenditure on health) 
Pharmaceutical expenditure as a % of Health 
Expenditure (% of total health expenditure) 
Total health expenditure as % of Gross 
Domestic Product 
Note: These are the 6 health system characteristics identified as independent variables 
for the study. 
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Literature Search Strategy 
Search Strategy 
The literature review for this study was executed by searching for and reviewing peer-
reviewed and academic literature from computerized databases and resources available at 
Walden Library: ABI/INFORM Global, Academic Search Premier, Encyclopedias from Sage, 
eBrary e-book collections, Education Research Complete, Expanded Academic ASAP, General 
Science Collection, Health and Medical Complete (ProQuest), Health Sciences: a Sage Full-Text 
Collection, IEEE Xplore Digital Library, InfoSci Journals, Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), MEDLINE with Full Text ProQuest Central, 
ResearchNow, Science Direct, SocINDEX with Full Text, and applicable academic textbooks.  
Additional search focused on online databases like google scholar, WHO website, 
UNICEF website, and those of other international non-governmental organizations that work on 
access to medicines and health systems in developing countries. These organizations included 
Management Sciences for Health (MSH), PATH, Population Service International (PSI), etc. 
Reference lists of some retrieved articles were also reviewed. 
Search Terms 
The following keywords were used alone and in combination as search terms: health 
systems, health care access, live-saving maternal health medicines, oxytocin, misoprostol, 
magnesium sulfate, post-partum hemorrhage, eclampsia, pre-eclampsia, access, medicines, 
pharmaceutical, essential medicines list. Only texts in English were reviewed, with most 
literature published between 2003 and 2016.  
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Scope of Literature Review 
The literature review included (a) peer-reviewed studies, including systematic reviews 
and meta-analysis; (b) studies that examined the association between maternal health medicines 
or access to medicines more broadly with one or more health system determinants; (c) studies 
published between 2005 and 2016; (d) studies published in English, and (e) studies published in 
all regions.  
Literature Related to Key Variables and/or Concepts 
Global statistics on maternal health: Every day, approximately 830 women die because 
of complications during pregnancy or childbirth (WHO, 2015). The WHO also estimated that by 
the end of 2015, roughly 303 000 women will have died during and following pregnancy and 
childbirth (WHO, 2015). An overwhelming 99% of these maternal deaths occur in low–resource 
settings. For instance, in 2015 alone, the maternal mortality ratio in developing countries was 
239 per 100 000 live births versus 12 per 100 000 live births in developed countries (WHO, 
2015). Over 50% of deaths in developing countries occur in sub-Saharan Africa and almost one 
third occur in South Asia. More than half of maternal deaths occur in fragile and humanitarian 
settings (WHO, 2015). 
Women in developing countries have on average, many more pregnancies than women in 
developed countries. Consequently, their lifetime risk of death due to pregnancy and related 
causes is higher (World Bank, 2012). For instance, the probability that a 15–year–old woman 
will eventually die from a cause related to maternal health is much higher for women living in 
low income countries than for those who live in high income countries (1:180 vs 1: 4900). In 
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countries designated as fragile states, the risk is 1 in 54; a consequence of breakdowns in health 
systems (WHO, 2015). 
Advances on Maternal Health: In 2000, 189 member states of the United Nations adopted 
eight Millennium Development Goals (MDG) (United Nations, 2000). The fifth MDG aimed to 
reduce maternal mortality worldwide by 75% between 1990 and 2015 with an annual average of 
5% (United Nations, 2000, United Nations, 2013). In sub-Saharan Africa, a number of countries 
halved their levels of maternal mortality since 1990. In other regions, including Asia and North 
Africa, even greater headway was made. Also, between 1990 and 2015, the global maternal 
mortality ratio (i.e. the number of maternal deaths per 100 000 live births) declined by only 2.3% 
per year. However, increased rates of accelerated decline in maternal mortality were observed 
from 2000 onwards. In some countries, annual declines in maternal mortality between 2000-2010 
were above 5.5%, the rate needed to achieve the MDGs. Despite a 43% decrease in maternal 
mortality from 1990 - 2014, the annual rate of decline has been far below the MDG 5 target 
(WHO, 2014; UN, 2013, 2015; Lozano et al., 2011). 
However, seeing that it is possible to accelerate the decline, countries have now united 
behind a new target to reduce maternal mortality even further. One target under Sustainable 
Development Goal 3 is to reduce the global maternal mortality ratio to less than 70 per 100 000 
births, with no country having a maternal mortality rate of more than twice the global average 
(WHO, 2015).  
The case for maternal health medicines: Most maternal deaths are preventable because 
health-care solutions to prevent or manage complications are well known: access to antenatal 
care in pregnancy, skilled care during childbirth, and care and support in the weeks after 
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childbirth. It is particularly important that all births are attended by skilled health professionals, 
because timely management and treatment can make the difference between life and death for 
both the mother and the baby (WHO, 2015).  
Based on these evidence, WHO provided recommendations for the essential interventions 
and medicines needed to improve maternal health and prevent these maternal complications 
[WHO, 2011b; WHO, 2012; WHO, 2013; WHO, 2012c). Oxytocin, misoprostol, and magnesium 
sulfate—are medicines that prevent and treat these two leading causes of maternal death 
worldwide: excessive bleeding after childbirth and high blood pressure during pregnancy. 
Oxytocin is recommended to prevent and treat excessive bleeding (post-partum 
hemorrhage) after childbirth. It is delivered through an injection. Misoprostol is recommended to 
prevent and treat excessive bleeding after childbirth when oxytocin is not available. It comes in 
tablets that are taken orally (Carroli, Cuesta, Abalos, & Gulmezoglu, (2008). Magnesium sulfate 
is recommended for treating high-blood pressure (pre-eclampsia and eclampsia). It is 
administered by an injection and needed at all levels of the health system where women seek 
care (WHO, 2012). 
The need for these three medicines are universal and present wherever deliveries occur: 
from urban hospitals to rural clinics and homes, where more than 50 percent of women in 
developing countries deliver their babies (Montagu, Yamey, Visconti, Harding, & Yoong, 2011). 
But women who do not receive the necessary antenatal care miss the opportunity to detect 
problems and receive appropriate care and treatment in the event of the pregnancy related 
complications (WHO, 2015). 
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While levels of antenatal care have increased in many parts of the world during the past 
decade, poor women in remote areas are the least likely to receive adequate health care during 
pregnancy and childbirth (WHO, 2015). This is especially true for regions with low numbers of 
skilled health workers, such as sub-Saharan Africa and South Asia. For instance, only 51% of 
women in low-income countries benefit from skilled care during childbirth and only 40% of all 
pregnant women have the recommended antenatal care visits. This means that millions of births 
are not assisted by a midwife, a doctor or a trained nurse. The high number of maternal deaths in 
some areas of the world therefore reflects these inequities in access to health services, and 
highlights the gap in the health system (WHO 2014). Expanding access to essential maternal 
health medicines would lower maternal death rates and improve maternal health (Wagstaff, 
2004).  
Studies Related to Key Constructs and Methods 
Oliveira et al (2002) carried out an implementation analysis to assess the success and 
quality of implementation of programs on access to pharmaceutical care by people living with 
HIV/AIDS in Brazil. Their approach focused on the process of producing outcomes and held 
relationships as a central tenant of how a program interacts within their organizational context. 
This approach allowed for continuous quality improvement because it takes into account the 
dynamic nature of the system and considers relationships and linkages across several 
components of the health system (Oliveira et al., 2002) 
Logie and Harding (2005) used a multi-method approach to evaluate Uganda’s morphine 
access program which handles chronic pain for cancer, HIV/AIDS and pain from sickle cell 
crisis. The program was evaluated from three perspectives – legislative, clinical, and community. 
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They used structured interviews, direct observation, and two sets of audits to capture the 
complexity of pain care delivery system in Uganda. This three-pronged approach combined with 
their consideration of the various aspects of the health system allowed Logie and colleagues to 
explore the unintended outcomes of the drug policy in Uganda as well as process barriers faced 
by various actors. It also allowed the authors to better predict the how the drug supply chain 
could affect end users and how to improve on it (Logie &Harding, 2005). 
Windisch et al (2011) used a mixed methods approach to explore the interaction within 
and across various components of Uganda’s drug supply management systems. WHO’s health 
systems framework for action that outlined seven health systems building blocks guided this 
systematic study. The study applied the principle of ‘path dependence’ to consider initiating 
conditions and the history of supply chain management in the country. Windisch et al (2011) 
captured perspectives through key informant interviews, and laid out how the different pieces of 
the system fits together, and how one part of the system affects the other. The authors also 
showed feedback loops that pointed out unintended effects. 
In 2012 also, Xiao, Zhao, Bishai, & Peters carried out a qualitative study in rural China. 
Their study evaluated a national drug policy’s implementation for its intended outcomes and 
unintended consequences. Xiao, et al., (2012) identified policy implementation actor involved 
and their roles. In depth key informant interviews were used to understand the motivations of the 
actors. They also considered the relationships and feedback loops created by the action and 
responses of these actors to the policy and system. This study accounted for the systemic changes 
caused by emerging patterns and activities by actors in a policy. A key finding from the study 
was that policy and behavior of certain actors give rise to behavior patterns by other actors which 
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in-turn give rise to self-organization, and a system that this is greater than the sum of its paths 
Xiao, et al., (2012).  
Another study in Iran looked at National Drug Authorities. In this study, Abdollahiasl et 
al., (2014) built a system dynamics model to visualize the effects of market variables involving 
the 5 P’s (Product, Price, Promotion, Place, People) on access, availability, affordability, quality 
and rationality (Abdollahiasl et al., 2014). The authors also created a stock flow diagram that 
allowed them to explore processes and evaluate policy approaches used to facilitate decision 
making. Their model simulated what the system flow and outcome would be - including positive 
and negative effects, with changes made at various levels of the system. Abdollahiasl and 
colleagues also suggested that their model can be manipulated depending on what researchers 
and policy makers would like to focus on as central concepts. For example, in this study, while 
affordability and availability were the core of the model, quality and rationality were also tested 
in terms of how they affect the system.  
Camaroon et al., (2009) did an analysis of secondary data on medicine prices, availability 
and affordability for 30 WHO essential medicines in 36 LMIC including some uteronics – which 
was only reported for a handful of countries. 
In 2010, Ridge et al. proposed the development and use of a fishbone diagram to rapidly 
assess the barriers and facilitators to the availability and use of MgSO4 in Zambia. They used 
this diagram as a conceptual framework to identify barriers and facilitators to the availability and 
use of magnesium sulfate. However, this was a smaller scale case study at the facility level and 
therefore did not explore factors across the health system based on interviews and focus groups. 
It did however provide a strong basis for demonstrating complexity in translating research to 
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practice, and it provided an effective way to understand barriers at the regulatory/government, 
supply, procurement, distribution, health facility and health professional levels. Sevene, et al 
(2005) did similar study in Mozambique and Zimbabwe where they reported on barriers to the 
use of MgSO4 in these countries. 
In their study to examine the inclusion of the priority medicines for maternal and child 
health on national essential medicines lists, Hill, Yang and Bero, (2012) examined publically 
available collection of the national essential medicines lists that have been submitted to WHO by 
member states in the last 10 years (WHO, 2016). Only countries that had the most-up-to date list 
in this time-frame were included in the study. Each EML was then evaluated for congruence with 
WHO “list of priority medicines for Mothers and Children 2011(Hill, et al., 2012). HIV 
medicines were excluded from the list because most countries have separate platforms for 
purchasing HIV medicines. ‘Missing’ were also excluded because these formulations either do 
not exist, or have not yet been fully commercialized. The authors compared specification of the 
drug as the International Nonproprietary Name (INN), dosage form, and strength dose 
combination of TB medicines is not available.  
Smit et al. (2014) carried out a key informant survey in 37 LMIC to identify both national 
and global gaps in PPH and PE/E program priorities and to highlight focus areas for future 
national and global programming. The survey looked at the three essential maternal health 
medicines of interest in this study, and consisted of a 44-item questionnaire that addressed 6 core 
programmatic areas: policy, training, medication distribution and logistics, national reporting of 
key maternal health indicators, programming, and challenges to and opportunities for scale up. 
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An interesting aspect of Smit et al. (2014) study is the inclusion of certain programming 
indicators that could serve as objective pointers to access and use of these medicines in LMIC. 
Bigdeli et al (2013) used mixed methods including policy document review, key 
informant interviews, focus group discussions and direct observation at health facility to explore 
use of magnesium sulfate for sever pre-eclampsia and eclampsia in Pakistan. They used a fish 
diagram to identify causal pathways and in the process highlighted barriers and enablers of 
access to magnesium sulfate. Their study considered the following levels of health system - 
individual, households and communities; health service delivery; health sector; national level 
beyond the health sector and international level. They conducted interviews and focus groups to 
capture the multitude of factors and actors at play in preventing or facilitating access to and 
appropriate use of magnesium sulfate; and to provide further interpretation of the fish diagrams 
nodes. Context specific health system barriers and enablers were identified and their capacity to 
affect access and use of magnesium sulfate was used to make policy recommendation.  
A major strength of their study was the triangulation of data sources and methods of 
collection – as it allowed for more comprehensive exploration of the different levels of the health 
systems as well as the various building blocks of the health system. Context specificity is also an 
important strength of this study in improving availability and use of medicines within the service 
delivery system used to map determinants of access to and use of life saving maternal health 
medicines at all five levels: health sector and health service delivery levels. 
Tran and Bero (2015) analyzed seven UNFPA/WHO reports published in 2008–2010. 
These reports summarized country–wide rapid assessments of access to and use of essential 
medicines for maternal health in Mongolia, Nepal, Laos, the Democratic People’s Republic of 
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Korea (DPRK), the Philippines, Vanuatu, and the Solomon Islands. Tans and Bero used a 
“fishbone” (Ishikawa) diagram as the analytic framework to identify facilitators and barriers at 
four health–system levels: government/regulatory, pharmaceutical supply, health facility, and 
health professional.  
Something of note is that the majority of these studies that explore access to uteronics 
used similar methodology, constructs and variables in their research. For instance, Smith et al., 
(2011) administered a 44-item survey addressing 6 core programmatic areas: policy, training, 
medication distribution and logistics, national reporting of key indicators, programming, and 
challenges to and opportunities for scale-up. Trans and Baro (2015) explored the following 
measures for oxytocin, Ergometrine and magnesium sulfate in their study: (1) need and demand, 
(2) availability, (3) presence on essential medicine lists, (4) inclusion in standard treatment guide 
lines and protocols, (5) rational use, (6) licensing and areas of quality assurance, (7) storage, (8) 
procurement and supply chain, (9) costs, and (10) coordination and integration between public 
and private collaboration efforts. A couple other studies (Tran and Bero, 2015, Ridge et al., 
(2010). Bigdeli et al., 2009; SeveneSevene, et al., 2005) considered health systems barriers and 
facilitators to access to one or a combination of maternal health medicines in LMIC. 
Health Systems and Access to Medicines 
Defining health systems: The WHO defines a health system as a system "whose primary 
purpose is to promote, restore, or maintain health" (WHO, 2000). According to WHO (2000), 
health system activities range from direct service provision through clinics and hospitals to 
community level prevention strategies and health education.  
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In other to ensure stakeholders have a shared understanding of what health systems are 
and actionable points for strengthening health systems, WHO developed a framework comprised 
of six building blocks of a health system: 1) health service coverage, 2) human health resources, 
3) health information systems, 4) medical products, vaccines and technology, 5) health financing, 
and 6) leadership and governance (WHO, 2007). These building blocks are expected to support a 
“health system that can prevent, treat and manage illness and to preserve mental and physical 
well-being for all individuals equitably and efficiently, within a specified geographic area” 
(WHO, 2007, p. 2). 
Defining and Measuring Access: Although the concept of access - broadly is commonly 
thought to be quite complex, researchers have explored the concept in health care since the 
1970’s, and have put forward a myriad of definitions (Srivastava, 2011; Donabedian 1972; Aday 
& Andersen, 1974; Penchansky, 1977; Gulliford, Figueroa-Munoz, et al. 2002; Oliver & 
Mossialos, 2004). In terms of measuring access, the literature does not present a clearly defined 
pattern for measuring access since multiple factors affect access to medicines including health 
facilities, service providers, money, knowledge and beliefs (Hausmann-Muela, 2003). However, 
it is common to find access being measured based on dimensions suggested in ‘access’ 
definitions and according to the particular access topic being investigated e.g. health care, 
medicines, etc.  
Service utilization - Donabedian (1972) defined proof of access to be the use of service 
rather than whether the facility exists – as suggested by other researchers. He also proposed that 
access should be distinguished between two components: initiation and continuation 
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(Donabedian 1972) Aday and Anderson’s (1974) point that the potential to utilize was distinct 
from utilizing a service or gaining access appear to align with Donabedian’s (1972) assertion. 
Similarly, Wagstaff & van Doorslaer, (2000) defined access as the utilization of health 
services or treatment. According to them, utilization of health services did not depend on the 
availability of treatment opportunities alone, but includes the extent to which individuals avail 
themselves of the opportunities (Wagstaff & van Doorslaer, 2000a). 
Interaction between individuals and a health system - Other researchers like 
Penchansky (1977), Mooney (1983), Oliver and Mossialos (2004) thought that access should not 
be only construed as utilization of health services, but should include the interaction between an 
individual and the health system. Access should also demonstrate a sync between demand and 
supply related factors (Donabedian 1972; Penchansky 1977; Gulliford et el., 2002; Oliver and 
Mossialos, 2004). It should relate to factors beyond time and monetary cost of seeking care (Le 
& 1982; Mooney,1983), but extends to include income (Olsen, & Rogers, 1991), services, 
quality, personal inconvenience, cost and information (Goddard & Smith, 2001).  
Accordingly, in 2002, Gulliford et al proposed the following dimensions as measures of 
access: Availability of Health service - which focuses on the supply and utilization of health 
services; Health service outcomes which depicts how relevant, effective and quality services are; 
Equity of access -  which relates to the extent to which people access services in proportion to 
their needs.  
Some researchers like Palmer (2008) have also proposed simpler measures like equality 
of expenditure (the extent to which monies spent on people are the same) or equality of 
utilization (the extent to which people equally use a health facility). 
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Similarly, Thiede et al. (2007) defined access more broadly as “freedom to use health 
services” (Thiede et al., 2007, p. 105). Their definition considered three dimensions: availability; 
affordability, and acceptability of health services. In their view, availability refers to the extent to 
which needed services are available, within geographical reach and equitably distributed across 
different population groups. Affordability refers to the financial access in the broadest sense (e.g. 
direct costs, indirect costs, household financial wealth). In this regard, other researchers have 
advocated for measures like use of health care, Out- of-Pocket (OOP) payments for health 
services, health status, mortality, or funding allocated from governments (Brockerhoff and 
Hewett, 2000; Dayton et al. 2000; Makinen, Waters, et al. 2000; Wagstaff, 2000b). Acceptability 
refers to how patients perceive health services including health worker attitude to patients, 
cultural attitudes of patients towards health care services, condition of premises, waiting times, 
duration of consultations, and quality of care in public versus private facilities. 
Access to Pharmaceuticals: Some researchers have used models of health services 
utilization to define access to pharmaceutical products because access to medicines is considered 
to be a subset of health services utilization (e.g., Kloos et al., 1986; Miralles and Kimberlin, 
1998). However, a couple of disadvantages exist with strictly using “utilization” to describe 
access (Aday & Andersen, 1981). Firstly, utilization does not capture all aspects of access. For 
instance, the difference between health service utilization and access to medicines is quite 
distinct: unlike health service utilization, both pharmaceutical products and pharmaceutical 
services impacts access to medicines. So defining access strictly by service utilization leaves out 
the opportunity to understand the role of pharmaceutical product characteristics in determining 
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access. It also does not reflect individuals who need health care but do not receive it (Aday & 
Andersen, 1981).  
Furthermore, utilizations may identify equity challenges in the distribution of health care 
services but it may not fully capture the appropriate level of quantity or quality of care (Thiede et 
al. 2007). For instance, the utilization pattern may be skewed towards lower income groups but 
this may be because the alternatives for the poorer segments of the population are unaffordable 
(Thiede et al. 2007). Consequently, access to medicines needs to be considered in terms of the 
service as well as the goods that are delivered by the service. 
In addition, Kloos et al., (1986) noted that when defining access to pharmaceutical 
products and services, it is important that definitions of access to pharmaceutical commodities 
extend beyond explaining utilization by “entry use” through a prescription from a health care 
professional to incorporate utilization patterns in the informal sector and in self-medication 
(Miralles and Kimberlin, 1998). This is because many drugs are available to the general public in 
a relatively uncontrolled environment. For most medicines, consumers are allowed greater 
leeway in personal decision making about drug use than are patients seeking care in treatment 
facilities (Kloos et al., 1986). 
Furthermore, the issue of ‘pharmaceutical integrity and bioequivalence of the product as 
well as the quality of the services that affect the appropriate use of the product’ comes to play in 
defining access to pharmaceuticals. In this regard, Miralles and Kimberlin, (1998) suggested that 
considerations for access to pharmaceutical products should incorporate access to information 
needed to make appropriate decisions regarding availability and use of the product. Information 
in this context include all aspects of drug supply chain including selection, procurement, 
29 
 
 
 
distribution and use. They should also address concern regarding the continuity or sustainability 
of access to pharmaceutical products and services, especially for use in chronic or endemic 
situations.  
Determinants of Access to Medicines 
In this section, we discuss the literature regarding determinants of access to medicines 
from two dimensions that appear to be common themes - theoretical propositions and empirical 
research findings. These represent rationale for selection of variables proposed for this study. 
Multiple Conceptual Propositions that attempt to explain factors that determine access to 
medicines are discussed in following paragraphs.  
WHO-MSH 2000 framework: WHO-MSH 2000’ ATM framework was the first 
‘Access to Medicines’ (ATM) framework that attempted to define how access to medicine 
should be measured from a health systems perspective. It was developed in 2000 during a WHO-
MSH consultative meeting in Ferney–Voltaire (Centre for Pharmaceutical Management, 2003). 
This framework was informed at the time by 1) WHO Medicines Strategy: Framework for 
Action in Essential Drugs and Medicines Policy, 2000–2003 (WHO, 2000), 2) Country 
experiences with using existing pharmaceutical sector indicators, and 3). Penchansky and 
Thomas’s (1981) 4As of access framework: ‘Availability’, ‘Accessibility(geographical)’, 
‘Acceptability’ and ‘Affordability’, with ‘Quality’ of products and services as a cross-cutting 
determinant – which also represents the dimensions for WHO-MSH framework. Also, each of 
the A’s had two demand and supply focused indicators.  
The WHO 2004 ‘Equitable Access Framework: The WHO 2004 ‘Equitable access to 
essential medicines’ framework was the next major access to medicine model that evolved. This 
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framework was developed because there was global recognition that in the last two decades prior 
to this time, tremendous progress had been made in ensuring access to medicines globally, but 
significant equity gaps remained (WHO, 2004). 
Not everyone had benefited equitably from global improvements in the provision of less 
costly and more effective treatments with essential medicines. The WHO (2004) model proposed 
that four dimensions of a system predicts access to medicines - 1) Rational selection and use, 
‘Affordable prices’, Sustainable financing, ‘Reliable health and supply system.  
Rational selection emphasize the need to rationalize medicine choices (WHO, 2004). In 
other words, countries needed to identify, give preference and promote access to those medicines 
that will have the greatest impact in a given health care setting – This concept was later referred 
to as essential medicines list (WHO, 2007). ‘Rational use’ proposes to improve use of medicines 
by consumers. That is, to ensure safe and effective treatments, and minimize the risks and waste 
linked to irrational prescribing and use of medicines through trained medical personnel’s and 
adequate diagnostic equipment’s. ‘Affordable prices’ relates to supply-side aspect of 
affordability. 
‘Sustainable financing’ is viewed in the context of overall health care financing, and 
addresses resource mobilization and pooling (public funding, donor assistance and development 
loans, donor funding for and donations of medicines), and reduction of out-of-pocket and 
catastrophic expenditures. The ‘reliable health and supply system’ dimension of the WHO -2004 
framework assume that among the many elements of an effective health and supply system, four 
elements are most important in supporting access to essential medicines are: Health sector 
development (human resources for health, health equipment’s, hospitals, etc.), public-private-
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NGO mix, regulatory control, procurement co-operatives, and Traditional and complementary 
medicines. 
Frost and Rich framework: Frost and Reich (2010) examined how poor people in poor 
countries access health technologies, including medicines. In their model, they adopted a 4A 
framework for ATM - though different from the WHO-MSH 4A model (Table 1.2): 
‘Architecture’, ‘Availability’, ‘Affordability’ and ‘Adoption’ are the determinants of access. In 
their framework, ‘Availability’ represents supply and includes manufacturing, forecasting, 
procurement, distribution and delivery functions. ‘Adoption’ represents demand at all levels. 
‘Affordability’ integrates costs, at government, non-government and end-user levels. All three 
are coordinated by organizational relationships at national and international levels, represented in 
the pharmaceutical ‘Architecture’ function. 
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Table 2 
 
Domains and Determinants Covered in Existing Frameworks for ATM 
ATM 
Framework 
Domains Specific Dimensions Cross-
cutting 
Determinants 
WHO-MSH 
2000 (Centre 
for 
Pharmaceutical 
Management, 
2003) 
Availability Medicines’ supply—type and quantity, 
Medicines’ demand—type and quantity 
Quality of 
products and 
services Affordability Prices of drug products and services, 
User’s income and ability to pay 
Acceptability Prices of drug products and services, 
User’s income and ability to pay, 
Characteristics of products and services 
User’s attitudes, expectations of products 
and service 
Accessibility Medicines’ supply location, User location 
WHO (2004c Rational Use Rational therapeutic choices, Improved 
medicines’ use by consumers 
Quality of 
medicines 
 Affordable Prices Medicines’ pricing policies, 
 Sustainable Financing Resource mobilization, Pooling, 
Reduction of out-of-pocket expenditures, 
Reliable health and supply systems 
 Reliable Health and 
Supply Systems 
Medicines procurement and supply, 
Regulation, Human resources 
Frost and Reich 
(2010) 
 
Availability  Manufacturing, Forecasting, 
Procurement, Distribution, Delivery 
Architecture: 
organization 
relationships 
at national 
and 
international 
level 
Affordability Government affordability, Non-
governmental agency, affordability, End-
user affordability 
Adoption Global adoption, National adoption, 
Provider adoption, End-user adoption and 
appropriate use 
Bigdeli et al’ 
2013 
Individual, household, 
Community 
Perceived quality of medicines and health 
services, Cost of medicines and services, 
irrational health-seeking behavior, 
demand for and use of medicines, Social 
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and cultural barriers (stigma related to 
poverty, ethnicity, and gender) 
Health service delivery Irregular availability, High medicine 
prices Irrational prescription and 
dispensing, Low quality/sub-standard and 
counterfeit medicines, Low quality of 
health services, Competition between 
public and private health service delivery 
 
Health Sector Pharmaceutical sector governance, 
Medicines price control,  
Weak health sector governance affecting 
all health system  
building blocks, Health sector pluralism 
and stewardship over private sector 
 
Public Policies Cutting 
Across Sectors 
Low public accountability and 
transparency, Low priority attached to 
social sectors 
High burden of government bureaucracy 
Conflict between trade and economic 
goals for pharmaceutical 
markets and public health goals 
 
International and 
Regional Levels 
Unethical use of patents and intellectual 
property rights, International donors’ 
agenda, Distorted research and 
development, not targeting disease 
burden in LMICs 
 
Source : Bigdelo et al., (2013) 
Bigdeli framework: In 2013, Bigdeli et al developed an ‘access to medicines from a 
health systems perspective’ model. This model was proposed as a paradigm shift from traditional 
access to medicines frameworks (discussed further latter in this chapter) which only partially 
addressed the full range of ‘access to medicines’ predictors. It is intended to promote a systems 
approach to improving access to medicines, to ensure that policies are more effective and 
generate longer-term equitable and sustainable results. 
34 
 
 
 
This 2013 framework proposed that different elements of a health system predict access 
to medicines: Characteristics of individuals, households and communities; resources, service 
delivery, and governance (Bigdeli et al., 2013). These elements interact with each other in 
multiple and dynamic ways, are supply and demand- driven, and occur at different levels: (1) 
individual, households and community level; (2) health service delivery level; (3) health sector 
level; (4) national level beyond the health sector (public policies cutting across sectors) and (5) 
international/regional levels (Bigdeli et al., 2013). Some authors categorize the ‘individual, 
households and communities’ elements as demand -side determinants, and resources, service 
delivery, and governance as supply side determinants (Ensor and Cooper 2004; Peters et al. 
2008; Jacobs et al. 2012). 
Bigdeli et al (2013) framework was based on recognition that previous models 
emphasized more of supply-side approaches to address demand-side constraints. Previous 
models also tended to focus more on products than service delivery. Except for the WHO-MSH 
(2000) model – which seems to be clearly centered on health service delivery, and the WHO 
health systems framework – which was more encompassing, all others centered on the 
medicines/medical products (Bigdeli et al., 2013). Bigdeli and colleagues also noted that 
governance in all three models focused on the pharmaceutical sector, and there are minimal 
linkages with national policies beyond the health sector. Their model considers equally, both 
supply and demand-side approaches, as well as products and services from both pharmaceutical 
and non-pharmaceutical perspectives. Their model also incorporates ATM predictors from both 
the health sector and non-health sector and advocates for approaches that weaves ATM into other 
aspects of a health system.  
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Findings from Past Research 
Socio-economic and demographic determinants: Different measures of equity and 
economic status have been considered as predictors of access in developing country settings 
(Wagstaff 2000b), Wagstaff (2000b) and colleagues looked at the population according to 
subgroups like wealth quintiles (Wagstaff, 2000b), gender and ethnicity (Brockerhooff & 
Hewett, 2000), health condition (Gakidou, Murray, et al., 2000) geographical location, age, 
education or occupation (Gwatkin, 2000b). Household consumption, expenditure, or asset 
ownership, are also common proxies used in the literature, and are considered better measures in 
these settings. Income data are not considered reliable measures because there can be under-
reporting. They can also be seasonally dependent and do not necessarily capture longer-term 
income or permanent wealth in low -income settings (Makinen et al. 2000; Palmer 2008).  
Social status is also commonly considered as predictors of access and education and 
occupation are more commonly used as proxies for social status. For example, data sets from the 
Demographic and Health Surveys allow analysis of household assets by creating an asset index 
and the application of principal component analysis (Filmer, & Pritchett, 2001). 
Heller (1982) and Dzator et al. (2004) also looked at distance and time as predictors of 
access. While distance is typically modelled as distance from health facility, time related 
information is analyzed as time spent traveling to the health facility, waiting time and treatment 
time. For example, Heller (1982) found that a 1% increase in waiting time will affect the 
probability of demand by -0.02% to 0.02%. Dzator et al. (2004) found that a 1% increase in 
distance will reduce the probability of demand for treatment by -0.36% at a public provider. 
However, a limitation with findings related to time and distance is that most studies use 
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aggregate level data rather than household level (Srivastava, 2011). It may be worth noting that 
the “time’ indicator has also been used as indicator for health service delivery. 
Health systems determinants: While systemic determinants may include a variety of 
factors, the literature regarding access to medicines and uteronic appear to be heavy on a few. 
The robustness of a public health system has been highlighted as a necessary component to 
achieve the Millennium Development Goals (MDG) (Farahani, Subramanian & Canning, 2009; 
Freedman et al, 2005). Hoppu, Ranganathan, & Dodoo, 2011; Oshikoya, and Senbanjo, (2010) in 
summary noted that reasons for the lack of essential medicines include fragile supply systems, 
out-of-pocket payments which make the medicines unaffordable, and poor quality products.  
Additionally, Ridge et al.(2010) identified the following requirements (or critical 
components) for adequate access to and use of MgSO4 in their Fishbone Diagram: inclusion of 
MgSO4 in National Essential Medicines List (NEML) and Standard Treatment Guidelines 
(STG), registration in the country for use in treatment of severe pre-eclampsia and eclampsia, 
presence of a suitable procurement and distribution system, presence of a suitable local protocol 
for use by health facilities providing basic and emergency obstetric care, awareness and adequate 
training of health professionals on the use of MgSO4 as first line treatment for severe pre-
eclampsia and eclampsia, availability of supplies and equipment to administer MgSO4 at facility 
level. These are discussed in greater details in following sections. 
Leadership, governance and policies - Muldoon et al (2011) found that the more 
corrupt a government is perceived to be (i.e. lower CPI score) the stronger the association with 
increased rates of infant, child and maternal mortality. As health systems are publicly 
administered and require strong national commitment and resources, a corrupt government runs 
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the risk of diverting public health resources for private gains (Pinzón-Flórez, et al., 2015). 
Corruption is also found to be an indication of “The establishment, application, and follow-up of 
rules for the health system; the extent to which there is equality of conditions for all the agents of 
the system; and, the definition of the strategic agents for the health system as a whole.” (Pinzón-
Flórez, et al., 2015). 
National policies were also identified as critical predictors of access to uteronics – the 
most popular being the presence of uteronic in global and national essential medicines list. Smith 
et al., (2014) found that countries that reported infrequent availability of misoprostol noted a lack 
of a national policy supporting misoprostol as a principle cause. Similarly, Tran & Bero, (2015) 
found that the first common facilitator of quality use of oxyttocine egometrin and magnesium 
sulfate at the government policy level was that all three essential medicines were consistently 
listed on national EMLs.  
Ridge et al. (2010) also identified inclusion of MgSO4 in National Essential Medicines 
List (NEML) and Standard Treatment Guidelines (STG), as precursor to adequate access to and 
use of MgSO4. Bigdeli, Zafar, Assad, & Ghaffar, (2013) found that lack of adequate translation 
of national policies into implementation arrangements was an important determinant of access to 
and use of MgSO4. They are related to fragmentation of procurement and supply based on 
demand from practitioners rather than on NEML or national policies Bigdeli, Zafar, Assad, & 
Ghaffar, (2013).  
Pharmaceutical supply system and market dynamics - Reasons for the lack of 
essential medicines include fragile supply systems (Hoppu, Ranganathan, & Dodoo, 2011; 
Oshikoya, & Senbanjo, 2010), (Hill, Yang & Bero, 2012) thought that essential medicines should 
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be manufactured according to quality standards, licensed for use by regulatory authorities, on 
essential medicines lists, part of national standard treatment guidelines, procured from the 
supplier of a quality product, in the supply chain, and prescribed by health care professionals 
who know how to use them (Hill, Yang & Bero, 2012). 
 In Zambia, the major barrier to availability within the public health system was lack of 
procurement by the Ministry of Health (Ridge, Bero, & Hill, 2010), (Javadi & Bigdeli, n.d) 
thought that information systems can also play a critical role in drug supply management and 
avoidance of stock-Outs - a central tenet to poor access. 
Sevene et al., (2005) identified a range of market and system failures that explained the 
use of MgSO4 in Mozambique and Zimbabwe: these include the low price of generic MgSO4 
which is a deterrent to effective marketing practices by pharmaceutical companies and a lack of 
specific public intervention to correct the situation. Accordingly, Bigdeli, Zafar, Assad, & 
Ghaffar, (2013) found that De-facto monopoly of a single pharmaceutical company and a small 
market creates disincentive for marketing MgSO4.  
Poor availability of magnesium sulfate may also reflect limitations of procurement 
systems. In one study, magnesium sulfate was not supplied to the lower levels of care because it 
was out of stock at the Central Medical Store (Ridge, Bero, & Hill, 2010). Affordable price of 
MgSO4 was added as a requirement.  
Quality of product and services - In 1993, McPake noted that quality is a difficult factor 
to capture in both cross-section and time series analysis, and this theme seem to be widely 
allured to in the literature. This is because quality as a variable has multiple dimensions – such as 
availability, affordability, health human resources, and health service delivery. These dimensions 
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also happen to be used in other themes regarding access - either as standalone indicators of 
access and use of medicines or as determinants of access. Quality cuts across multiple levels of 
the health system including health service delivery, human resources, trainings, and products. 
As a result, most quality and access studies are unable to capture some important 
dimensions of quality such as process and outcome (Sepehri and Chernomas 2001). They are 
also unable to control for the marginal influence of covariates. For example, drug availability – a 
widely used measure of quality in access to medicines is an important factor for patients but this 
measure is influenced by both demand and supply factors (Sepehri and Chernomas 2001).  
That said, studies on quality for access have produced mixed results of its effect on 
utilization. While some studies suggest that perceived quality of care is an important predictor of 
health care utilization and success of health system financing reforms (Annis 1981; Wouters 
1991; Barnum H and Kutzin J 1993; Lavy and Quigley 1993), others suggest otherwise. For 
instance, Bitran (1989) and Yoder (1989) found that utilization was lower where quality of care 
was perceived to be lower. Hutton (2004) and James et al. (2006) also had similar findings - 
utilization in smaller phased-in programs increased when combined with quality improvements.  
Chalker (1995) found that an increase in drug availability led to increases in utilization 
after an initial drop due to the introduction of user fees. However, Deolalikar (1998) noted a 
couple of years later that even though drug availability provides useful information, it only 
captures one relevant aspect when used in and of itself, and cannot account for whether it would 
imply better treatment.  
Wouters (1991) report of Denton, et al. (1990) and Akin, et al (1990) findings also 
indicated that in a region of Nigeria three aspects of quality were significantly associated with 
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utilization: percentages of years’ drugs are available, operational cost per capita, and facility 
condition.  
In contrast, Annis (1981) found that rural health posts had reasonable good quality of 
services but were not used. Denton, et al. (1990) and Akin, et al (1990) findings also indicated 
that machinery (x-ray machine and laboratories), number of support personnel, nurses and 
doctors per capita were not significant as well. In the same studies, investment in quality 
improvements were not offset by the revenue generation from user fees (Denton et al., 1990). 
Service delivery affects how medicines can reach patients and the extent to which 
rational use of medicines are upheld and promoted (Rouse, 2008; Javadi, and Bigdeli, (n.d). 
Well- trained human resources are required for improved diagnoses, prescribing and dispensing 
practices as well as for supporting adherence to drug regimens where home - based care is 
necessary.  
Also, a measure of quality as the probability of being seen by a physician was 
insignificant (Heller 1982; Mwabu, Ainsworth M et al. 1993). In the same vein, Muldoon et al 
(2011) used an amalgamated measure (i.e. nurses, doctors, skilled birth attendants) for human 
health resources and found that physician density, and health financing as measured by less out-
of-pocket payments were associated with decreased mortality for infants and children. Ridge, et 
al., (2010) also found that a lack of in-service training in the use of a specific medication was a 
barrier to access to that medication.  
Ridge et al (2010) identified access to antenatal care services as a requirement for access 
to and use of MgSO4. They also noted that lack of demand by health professionals at the health 
center level negatively affected access to MgSO4. Bigdeli, Zafar, Assad, & Ghaffar, (2013) 
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found that lack of adequate translation of national policies into implementation arrangements 
was an important determinant of access to and use of MgSO4. They are related to fragmentation 
of procurement and supply based on demand from practitioners rather than on NEML or national 
policies.  
Ridge, Bero, & Hill, (2010) noted that persisting practices of using diazepam or 
immediate referral without stabilization also acted as bottlenecks to access of MgSO4. In their 
study, there were no local protocols nor referral guidelines, and therefore little support for health 
staff to use MgSO4. However, the fact that drugs are produced locally served as an enabler to 
access because the country is able to navigate the challenge of international issues, and price is 
lower, hence affordable.  
Another enabler based on finding from Ridge, and colleague’s study (2010) is that 
procurement was based on NEML, and health professionals were trained to administer and 
diagnose pre-eclampsia, and eclampsia. The fact that Magnesium sulphate was not supplied to 
the lower levels of care because it was out of stock at the Central Medical Store, served as a 
deterrent (Ridge, Bero, & Hill, 2010).  
Haddad and Fournier (1995) found that in a rural setting in Zaire, a steady supply of 
drugs did not reverse a reduction in utilization, the competence of health care professionals, and 
the improvements in infrastructure and machinery. These findings were similar to those of 
Mwabu (1993) who found that greater availability of medicines had a negative relationship on 
utilization. But, Ridge et al. identified access to antenatal care services as a requirement for 
access to and use of maternal health medicines. They also noted that lack of demand by health 
professionals at the health center level negatively affected access to these medicines.  
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Health and pharmaceutical financing - Financing systems are a major bottleneck to 
access due to low affordability of drugs; without national policies to give universal access to 
essential medicines, those living below the poverty threshold are unlikely to access medicines 
when necessary (Javadi & Bigdeli, (n.d). Leadership and governance play an important role in 
preventing corruption and sale of drugs in black markets; regulation also serves to mitigate 
problems of counterfeits and substandard medicines (Javadi & Bigdeli, (n.d). 
A limitation with studies that considered quality is that most of them were small scale, 
had short time horizons and lacked robust methods and design (e.g. randomized) (Srivastava, 
2011). According to Srivastava, (2011) for most studies, findings were based on observation 
rather than modelling. As a result, it is difficult to properly assess the impact of quality on 
utilization.  
Review and Synthesis of Studies Related to Key Independent and Dependent Variables 
Many LMIC have elements in place to ensure access to essential maternal health 
medicines for addressing PPH and PE/E, but notable gaps remain in both policy and practice 
(smith et al., 2014). In this section, some of these as featured in the literature are presented. The 
availability of functional drug registration systems and manufacturing practices, and licensing 
status are also considered.  
Medicines in Essential Medicines List: In 2007, WHO found that 131 of 151 countries 
surveyed had an essential medicines list (Hill, Yang & Bero, 2012). Twenty-four of the national 
essential medicine lists were last updated prior to 2007. There was one list from 1999; but all 
others prior to 2007 were from 2001 to 2007. The four priority medicines most recently added to 
the WHO Model Essential Medicines List were misoprostol, cefixime, nifedipine, and zinc, all 
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added in 2006. The more up to date lists were more likely to contain the four medicines added in 
2006 than the older lists (Hill, et al., 2012). 
Hill, et al., 2012) found considerable global variation in the listing of Priority Medicines 
for Mothers on national essential medicines list. Their findings demonstrated that for prevention 
and treatment of postpartum hemorrhage in women, oxytocin was more prevalent on the lists 
than misoprostol - included on 55 (62%) and 31 (35%) of lists, respectively – although 
misoprostol was more likely to be listed on country essential medicines lists in the WPRO region 
than any other region. (Hill, et al., 2012).  
The authors (Hill et al., 2012) suggested that one reason for this may be that key opinion 
leaders in the region argued for the inclusion of misoprostol because, unlike oxytocin, it does not 
require refrigeration. In their view, the lack of cold storage in the region may have convinced 
medicines selection committees to add misoprostol. On the other hand, Magnesium sulfate 
injection for treatment of severe pre-eclampsia and eclampsia was on 50% (45/89) of the lists 
although they were not included consistently in national documents. Cefixime, for treatment of 
uncomplicated anogenital gonococcal infection in woman was on 26% (23/89) of lists.  
Tran and Bero (2015) also observed that Oxytocin was included in the essential medicine 
lists (EML) of all seven countries they assessed. However, In Mongolia and the Solomon 
Islands, ergometrine was not listed on the national EMLs. It was however, licensed for use in 
three countries (Nepal, DPRK, the Philippines). Ergometrine and Syntometrine were 
recommended as first–line drugs for PPH in Vanuatu and on the Solomon Islands, respectively. 
MgSO4 injection - recommended for the prevention and treatment of eclampsia in women with 
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severe pre-eclampsia was also included as an essential medicine in the national EMLs of all 
seven countries. 
Availability of Guidelines and Indications for Use: Tran and Bero (2015) found that 
Indications for use of Oxytocin were included in the EMLs of six countries, with the exception 
of the Philippines. A functional drug registration system in compliance with WHO–Good 
Manufacturing Practices guideline existed in all countries except the Solomon Islands. Data for 
oxytocin licensing status was not consistently reported across all seven countries. However, none 
of the oxytocin formulations were licensed in Laos. Standard treatment guidelines recommended 
oxytocin as a first line medicine for prevention of treatment of PPH in Laos, DPRK, and the 
Philippines. In contrast, Vanuatu and the Solomon Islands recommended ergometrine or 
syntometrine (combination of oxytocin and ergometrine) as a first - line drug treatment, which 
was not consistent with WHO evidence–based recommendations.  
Indications for use of MgSO4 injection - recommended for the prevention and treatment 
of eclampsia in women with severe pre-eclampsia were clearly provided with the exception of 
the Philippines. In Laos, the recommended formulation (50% solution) was not found to be 
licensed or available; 20% and 15% formulations were observed in facilities. DPRK was the only 
country which reported translating and utilizing treatment guidelines for pre–eclampsia and 
eclampsia in partnership with WHO, UNFPA, and other national professional associations. 
Furthermore, across all seven countries assessed in Tran and Bero’s (2015) study, 
standard treatment guidelines were inconsistent, out–of–date, and not widely disseminated. In 
Vanuatu and on the Solomon Islands, Standard treatment guidelines for prevention and treatment 
of PPH and the use of ergometrine were unavailable or not updated according to the most current 
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WHO clinical guidelines. These countries recommended ergometrine or syntometrine 
(combination of oxytocin and ergometrine) as a first - line drug treatment, which was not 
consistent with WHO evidence–based recommendations.  
In contrast, Laos, DPRK, and the Philippines recommended oxytocin as a first line 
medicine for prevention of treatment of PPH in line with WHO recommendation, the Standard 
treatment guidelines. But overall, the use of Egometrine as second-line treatment for prevention 
and treatment of PPH when oxytocin is unavailable or when bleeding does not respond to 
oxytocin was limited by its side effects and contraindication in patients who have high blood 
pressure. 
Availability and Demand: Regarding availability of the three essential maternal health 
medicines, Tran and Bero (2015) found that availability of the three medicines varied by country 
and medicine. Oxytocin for example had high availability in six out of seven countries studied 
compared to ergometrine. The two exceptions were the Philippines and the Solomon Islands, 
where ergometrine was available in a higher percentage of facilities than oxytocin. In the same 
study, four countries had MgSO4 available in less than 60% of their facilities, with only 18% of 
health facilities carrying MgSO4 in Laos. According to them, calcium gluconate, a required 
antidote for MgSO 4 toxicity, was not consistently available when MgSO4 was present.  
Similarly, Smit et al (2014) found that the vast majority of countries (34 of 37, or 92%) 
also reported regular availability of oxytocin in the national medical store or warehouse. 
Oxytocin and magnesium sulfate were also reported to be regularly available (available ‘more 
than half the time’’) in facilities in 89% and 76% of countries, respectively. However, only 27% 
of countries studied, however, noted regular availability of misoprostol in health facilities (smith 
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et al., 2014). The 4 countries that reported that oxytocin was not regularly available were 
Bangladesh, Liberia, South Sudan. Smit et al (2014) also noted that evidence collected from 
maternity units of hospitals with more than 1000 deliveries in Mexico and Thailand shows that 
MgSO4 is underutilized in women with eclampsia. 
Hill, et al., (2012). Found that demand for MgSO4 at the health center level was 
apparently low, it was not clear however, if the problem of availability was due to lack of 
demand leading to a lack of supply or vice versa (Ridge, Bero, & Hill, 2010). Where there was 
demand by obstetricians, magnesium sulfate injection was being procured from the private sector 
by the hospital pharmacy despite not being registered and licensed for use for the treatment of 
severe pre-eclampsia and eclampsia by the national Medicines Regulatory Authority. However, 
as this assessment did not include an audit of clinical data it is not clear if this was because there 
were in fact few cases or that cases were being misdiagnosed (Ridge, Bero, & Hill, 2010). Cases 
of pre-eclampsia were infrequent at small hospitals. 
Affordability of maternal health medicines: In terms of affordability, these medicines appear 
to be mostly provided for free. In Smith et al., (2014) study, about 70% of the countries (26 of 
37) reported that oxytocin was provided for free to clients at public health facilities. In 9 
countries, however, respondents reported that clients sometimes had to pay for oxytocin, even 
though national policy indicates that it should be provided at no cost. A substantial number of 
countries (25 of 37), however, also included diazepam for the same indication. Of the 20 SDGs 
reviewed, 6 showed incomplete or inaccurate instructions for the use of magnesium in severe 
PE/E, compared with the WHO standard protocol for use of the drugs. 
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Accessibility of maternal health medicines: Only 51% of women in low-income countries 
benefit from skilled care during childbirth (WHO, 2015). Most countries (31 of 37, or 84%) 
reported that midwives/skilled birth attendants (SBAs) were authorized to perform AMTSL, 
including administration of oxytocin. Fewer (29 of 37, or 78%) reported that midwives/SBAs 
were authorized to diagnose severe PE/E and to administer magnesium sulfate to treat the 
condition. Fewer still (26 of 37, or 70%) reported that midwives/SBAs were authorized to 
perform manual removal of the placenta. Also, sixteen of 37 countries (43%) reported that they 
were piloting or had piloted misoprostol for prevention of PPH at home birth; only 5 of 37, 
however, reported efforts to take this program to national scale. In follow-up qualitative 
responses, 7 countries reported that their governments do not support misoprostol for use at 
home births. 
 
Operational Definition of Terms 
Antenatal care: Represents the care given to pregnant women before birth by skilled 
health personnel that includes health promotion, screening of risk factors, and treatment of 
diseases and pregnancy-related complications (WHO, 2000). 
Health System: consists of all organizations, people and actions whose primary interest is 
to promote, restore or maintain health (Zaidi, et al., 2013).  
Health system factors: The features that characterize a health system in accordance with 
the WHO six building blocks framework. These include leadership and governance, human 
resources, supplies, financing, health information, and service organization (Muldoon et al., 
2011). 
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Essential Medicines: Medicines that respond to the priority health needs of a specific 
population (WHO, 2007).  
Essential maternal health medicines: Medicines needed to prevent and treat pregnancy 
and childbirth related complication (WHO, 2007). In this study, these medicines will include 
oxytocin, MgSO4, and Misprostol. 
Access: Availability at all times, adequate amounts, appropriate dosage forms, cost 
effective, proven efficacy, quality & safety (WHO, 2014). In this study, it refers to availability at 
all times, affordability and accessibility. 
Availability of medicines: presence of oxytocin, MgSO4, and Misoprostol in health 
facilities and central medical stores; and the frequency of oxytocin and MgSO4 stock outs in 
health facilities and central medical stores. 
Accessibility of Medicines: Misoprostol is piloted for home births, misoprostol is scaled 
up for home births, and number of ANC visits.  
Affordability of Medicines: Medicines are freely available to women in the health facility 
and at home births. 
Assumptions 
Assumption 1  
The data on access to medicines as well as health systems components may be under-or 
overestimations of the current situation and may introduce bias in the weighted results. The last 
survey took place about 2012. Since then, the multiple countries in the survey has experienced 
repeated political and economic instability. The current statistics are based on MCHIP and WHO 
49 
 
 
 
projections and may be far from reality. Using these estimates could result in under- or 
overestimated results. 
Assumption 2  
Countries studied were representative of the other countries in the region. The process of 
purposive sampling helped in selecting an unbiased sample of countries with maternal health 
programs. 
Assumption 3  
I assumed that the data were complete and accurate and that the study participants’ 
answers were unbiased. Thus, I assumed that the data quality assurance and verification 
measures were effective in minimizing the risk of inaccurate information recording, in particular, 
duplication, wrong coding, and missing data. Additionally, I assumed that the study participants 
were truthful in their answers and did not provide socially desirable responses. 
 
Scope and Delimitations 
This study assessed the relationship between one dependent variable (access to essential 
maternal health medicines) and six independent variables (health system characteristics). In line 
with Ishikawa diagram – a complex adaptive system model, the study will examine a subset of 
determinants that could be related to access to maternal health medicines. For this reason, the 
selection of the independent variables prioritizes health system characteristics.  
The choice of the cross-sectional design meant that the analysis aimed to establish the 
associations, not the cause-and-effect relationships or the reasons for these associations. This 
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study was limited to establishing the relationships between the health system characteristics and 
women’s access to essential maternal health medicines. 
For this project, study participants are represented by country programs for the 
prevention and management of postpartum hemorrhage and pre-eclampsia/eclampsia. The 
geographical areas of focus included countries in Africa, Asia, and Latin America, focusing on 
those USAID priority countries that face the highest burden of maternal morbidity. The results of 
this study are generalizable to the women needing access to essential maternal health medicines 
in the study areas.  
Limitations 
The study used a cross-sectional survey design that did not allow for manipulation of the 
independent variables or establishing the temporal sequence of events. For that reason, this study 
design could not establish a cause-and-effect relationship. In addition, the lack of manipulation 
may have weakened the study’s internal validity.  
Although the selection of study participants with ongoing national programs for 
prevention of PE/E was intended to minimize recall bias, there may have remained a likelihood 
of recall bias because study participants had to pull data from already existing sources. 
Furthermore, the use of secondary data may result in missing other important variables 
for the analysis. The analysis will depend on the data collected through the MCHIP 2012 global 
survey and the WHO Pharmaceutical sector country surveys. Therefore, this study did not 
identify all possible factors associated with access to maternal health medicines; variables not 
collected through the MCHIP surveys and WHO Pharmaceutical sector country surveys will not 
be analyzed.  
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Summary, Significance, and Conclusions 
Although reduced in recent years, maternal deaths due to Preeclampsia, Eclampsia, and 
PPH remains high. These pregnancy-related complications and resulting maternal deaths are not 
distributed evenly across the globe, but disproportionately affect women living in resources poor 
settings. To reduce the incidence of these deaths, WHO recommends that oxytocin is provided as 
a first-line PPH preventive intervention for facility-based deliveries and Misoprostol as an 
alternative for oxytocin – which can also be used for home deliveries. MgSO4 is to be used for 
treatment of PE/E. 
Global and national organizations alike have implemented interventions to promote 
access to these essential maternal health medicines but gaps remain. Poor and vulnerable women 
still lack sufficient access to these medicines – as illustrated by current high maternal mortality 
ratios in these regions. There is evidence showing that the vertical approaches that characterize 
these efforts are not as effective as horizontal approaches that consider holistically, the dynamic 
interaction between components of the health system and access to medicine. According to the 
literature, the role of medicines is often narrowed down to a single isolated health system input 
instead of an integral part of a functioning health system that affects and is affected by other 
components. In this regard, the literature shows that in other to improve access to essential 
maternal health medicines, it is critical to understand and incorporate the full spectrum of the 
health system in research and practice regarding access to maternal health medicines (Paina and 
Peters, 2011; Bigdeli et al., 2013; p.2; (Adam, Ahmad, Bigdeli, Ghaffar, & Røttingen, 2011).  
These recommendations - though recently recognized - appear to be characterized by 
debates regarding 1) how access to medicines should be defined, 2) which health system input 
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affect access to medicines, and 3) how each health system input interact with each other and with 
the desired outcome – access to and use of medicine.  
In the early days, access was defined mostly from a supply side perspective. People were 
thought to have access to health services if facilities that provided the services were present. But 
subsequent studies started to demonstrate that this approach was less than comprehensive 
because the potential to utilize a service should be perceived as different from actually utilizing a 
service. Hence access should be defined and measured by actual utilization of service. Other 
studies further suggested that this definition should go beyond utilization to include the extent to 
which clients are able to continue utilizing services if needed.  
While these dimensions of access may be applied to measuring access to pharmaceutical 
products like essential maternal health medicines, researchers suggest that they present with 
limitations if applied on their own. For example, defining and measuring access to 
pharmaceuticals through the lens of service utilization would not be sufficiently objective since it 
fails to account for the characteristics of the product delivered through a given service. It also 
leaves out the role of some pertinent demand and supply related factors that are typical to 
pharmaceutical products and are important aspects of a functioning health system.  
As a result, a unique dimension was added by other researchers. In their view, access 
should be defined by the degree of interaction between supply (the health system) and demand 
(individual and household) related factors. In the last two decades, interest on this interaction 
seems to have increased.  
Multiple frameworks have evolved. Most emphasize the 4As proposed by earlier 
researchers (Availability, Affordability, acceptability, Accessibility) but present more broadly, 
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dimensions that represent access constraints beyond the health sector. Dimensions recommended 
include factors related to the availability, affordability, and acceptability of products, health 
service outcomes, equity of access, and equality of expenditure. Examples of factors in these 
regard include time and monetary cost of seeking care (Le & 1982; Mooney,1983), household 
income, service quality, personal inconvenience, cost and information. 
Other dimensions include those related to governance and policies internal and external 
to the health sector of a country. They include factors like public accountability and 
transparency, bureaucracy in governance and dynamics of trade and economic goals for 
pharmaceutical markets. International level influence like donor priority/agenda are also 
highlighted as key determinants of access to medicines. 
However, studies on the relationship between these factors and access to maternal health 
medicines appear limited – both in number and scope (Bigdeli et al., 2012). They tend to focus 
on examining the relationship between single or a few select combination of health system 
factors on access to medicines, comparatively across countries – (on one occasion (Smith, 2011; 
Trans and Bero, 2015; Bigdeli et al., 2015). While some use implementation research methods – 
i.e. looking at how the quality of implementation program affect access - most were mixed 
methods studies that included structured interviews, observations, and periodic audits. In terms 
of analytical framework, some studies use the WHO health system framework, while the fish 
bone Ishikawa diagram appear more popular with studies on access to essential maternal health 
medicines. Common health system dimensions studied include governance and leadership, health 
service delivery, pharmaceutical supply systems, financing, and human resources for health. 
Common Access indicators include availability affordability, acceptability and rational use. 
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In terms of predictors of access, the most obvious themes observed in the literature 
included governance, pharmaceutical supply system and quality of products and services – 
although the impact of quality on access seem mixed –since quality is cross-cutting and touches 
on several core levels of a health system. Common governance indicators observed include – 
presence on essential medicines list, availability of necessary regulation, and national corruption 
index. Pharmaceutical supply system indicators appear to be procurement and logistics related. 
Examples of quality indicators that facilitate access include perception of clients, availability of 
services, efficiency of service delivery infrastructures, access to antenatal care services. 
However, in one study, physician density - though used as measure of quality - was not 
significantly associated with access. 
According to the literature, most countries studied seem to have medicines on EML, but 
global variations exist. Overall Oxytocin was more prevalent on lists compared to Misoprostol. 
However, misoprostol was more likely listed on WPRO region than any other region. Inadequate 
provision for preservation was cited as a reason for this – since oxytocin require refrigeration but 
misoprostol does not. Availability of Standard Treatment Guideline seem inconsistent across 
countries. There seemed to be more demand for Oxytocin than for MGSO4. However, where 
there was demand for MGSO4, it was procured from private sector – even in countries where it 
is not being licensed for use for treatment. Availability of medicines in health facilities and 
central stores seems to vary by country and medicine. All three medicines seem affordable in 
most settings – as most are provided for free. Although in a few countries, women are made to 
purchase them, even when a national policy say it should be free. Accessibility is largely 
55 
 
 
 
impaired by poor access to skilled care, plus in most countries, midwives are not authorized to 
diagnose PE/E and administer MGSO4.  
In conclusion, several factors are said to predict access to medicines more broadly. But, 
little is known about the relative impact of these dimensions on access to essential maternal 
health medicines. In order to best understand how innovations and interventions will affect 
access to essential maternal health medicines, the open and dynamic relationships that exist in a 
health system should be analyzed more so across geographies. Predicting patterns of emergent 
behavior from various sources will serve to enhance understanding and to better plan and 
evaluate interventions that can lead to improved access to medicines and in turn better health 
outcomes for women (de Savigny & Adam, 2009; Anderson and McDaniel, 2000; Plsek, & 
Wilson, 2001). 
In this quantitative cross-sectional survey, I used the Ishikawa model as theoretical 
framework to examine the relationship between health system factors and women’s access to 
essential maternal health medicine in Low and Middle-income Countries (LMIC). The Ishikawa 
diagram was suitable for this cross-sectional analysis since it allowed for accounting for various 
factors that potentially predict access at various levels, and has been previously applied to similar 
studies. 
The evidence from this study could guide health policy makers and program managers in 
their efforts to build a health system that is responsive to the needs of rural women and children 
to save lives among vulnerable populations. Because of resource and data constraints, this study 
did not compare the relative impact of all factors predicting access to essential maternal health 
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medicines in all geographies. So analysis was limited to a few select health system indicators in 
some low and middle-income countries.  
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Section 2: Research Design and Data Collection 
 
Introduction 
This chapter describes the proposed research design and rationale, including the study 
variables, the design’s connection to the research questions, and constraints related to the chosen 
design. It includes the methodology—in particular, the study population, sampling technique, 
procedures, measurement instruments, and data analysis plan. It also highlights the threats to 
internal, external, construct, and statistical conclusion validity, and describes the ethical 
procedures that will be followed, including Institutional Review Board (IRB) approvals, and 
ethical concerns related to data collection and confidentiality. 
 
Research Design and Rationale 
This study was a quantitative cross-sectional survey using secondary data to determine 
the relationship between health system characteristics and access to three essential maternal 
health medicines. Cross-sectional surveys are commonly used research design in social sciences 
(Frankfort-Nachmias & Nachmias, 2008). The cross-sectional survey design used had some 
advantages and limitations. Some limitations include that it did not allow me to manipulate the 
independent variables or sequence the occurrence of events. For that reason, causal inferences 
and before-and-after comparisons was not possible (Frankfort-Nachmias & Nachmias, 2008). 
Further, it may have introduced recall bias since primary data was collected from information 
collected in the past (Rossetti, 2015). 
Despite these limitations, the cross-sectional survey design was most appropriate for this 
non-experimental analysis. It gave a snapshot of the situation in the study location and allowed 
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for comparison between different or similar geographies at a point in time. This design also 
allowed for ease of administration of data collection materials telephone interviews, online 
platforms, mobile devices, mail, email, or computer kiosks. It also allowed for collection of large 
amounts of data to increase statistical power and allow more sophisticated analysis. It was cost 
effective when compared with experimental and cohort studies (Rossetti, 2015). As such, the use 
of secondary data for analysis in this study saved cost and time, and enhanced the privacy of 
study participants (Frankfort-, Nachmias & Nachmias, 2008). 
Study Variables 
The study aimed to investigate the nature of association between health system 
characteristics (the independent variables) and access to three essential maternal health 
medicines – the dependent or outcome variable. Frankfort-Nachmias and Nachmias (2008) 
defined dependent variables as those for which researchers work to explain change, and 
independent variables as those that explicate change in the dependent variables.  
The independent variables were health-system characteristics that may influence 
women’s access and use of these medicines. In this regard, five health system levels or domains 
was assessed: government and regulatory, pharmaceutical supply system, health facility, health 
financing, and health professional (health services). For each domain, two to three health system 
variables that best represent a domain were analyzed (table 3.1). The outcome variable for this 
study was ‘access’, defined as the availability, affordability and accessibility three essential 
maternal health medicines combined (Oxytocin, Egometrin and Magnesium Sulfate).  
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Table 3 
 
Health System Determinants of Access to Maternal Health Medicines 
Variable/Domain Questionnaire Item 
  
Governance/Regulation 1.Medicines approved at national level 
 2. Availability of Standard Treatment 
Guidelines 
 3. Policy provision for AMTSL 
 4.Good Governance 
Pharmaceutical Supply 5.Procurement/ Logistics 
Health Facility 6. Adequate Equipment’s and Supplies 
 7. Education/Trainings 
Service Delivery 8. Adequate human resources 
 9. Midwife/skilled birth attendants scope of 
practice 
Health Financing 10.National Health spending 
Note. These are the 5 health system characteristics identified as independent variables for the 
purpose of this study 
 
Research Design Connection to the Questions and Scientific Knowledge 
This study investigated the relative effect of selected health system factors on access to 
three live-saving maternal health medicines (Oxytocin, Misoprostol and Magnesium Sulfate). 
Past research has examined similar questions through mixed-method studies without 
manipulation and secondary data analysis of cross-sectional surveys. In that regard, the cross-
sectional survey design used in this study has remained a popular research design in studies of 
the determinants of access to medicines and health systems (Ridge et al., 2010; Bigdeli, Zafar, 
Assad, & Ghaffar, 2013; Muldoon et al (2011; Denton, et al.,1990; and Akin, et al., 1990) 
A cross-sectional household survey was considered more relevant for this study because 
of the paucity of data on access to live saving maternal health medicines. This study was 
implemented as a secondary analysis of data from quantitative cross-sectional facility and 
household surveys conducted independently by the World Health Organization (WHO) and the 
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United States Agency for international development (USAID) Maternal and Child Health 
Integrated Program (MCHIP). 
As Frankfort-Nachmias and Nachmias (2008) observed, a secondary data analysis is less 
expensive than studies requiring primary data collection. In advancing knowledge, this study will 
be an initial step in establishing the relative effects of health system characteristics and access to 
essential maternal health medicines. It will lay the ground for further studies.  
Methodology 
Target Population  
The USAID MCHIP survey included countries from Africa, Asia and Latin America - 
focusing on those USAID priority countries that face the highest burden of maternal morbidity. 
The WHO survey proposed for this study – the WHO pharmaceutical sector country survey was 
a comprehensive assessment of the pharmaceutical sector in countries in the same region. 
Settings 
The WHO pharmaceutical sector survey was implemented in nearly all WHO countries. 
In 2010, the country profiles project was piloted in 13 countries during 2011, the World Health 
Organization had supported all WHO Member States to collect similar pharmaceutical country 
data. It is a comprehensive assessment of the pharmaceutical sector aimed to measure key 
aspects of the pharmaceutical sector and systematically monitor the progress of efforts to 
improve access to essential medicines.  
The USAID MCHIP survey assessed 37 national programs for the prevention and 
management of PPH and PE/E. The survey has been implemented twice (2011 and 2012). It 
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captured a cross-section of countries that are either priority countries within USAID’s global 
health strategy, or engaged in relevant maternal mortality reduction efforts. 
Sampling and Sampling Procedures  
A sample is a subset of sampling units that has the attributes of the target population. It 
has to be representative to allow generalization of the findings to the entire population 
(Frankfort-Nachmias & Nachmias, 2008). In this study, the sampling unit was a country that 
implemented a national program for the prevention and management of PPH and PE/E, and 
participated in USAID MCHIP survey.  
There are two main sampling designs: probability sampling and nonprobability sampling. 
This study will use the purposive non-probability sampling to base on set criteria (Frankfort-
Nachmias & Nachmias, 2008). The inclusion criteria were countries with a national program for 
the prevention and management of PPH and PE/E who participated in the USAID MCHIP 
survey. The exclusion criteria included countries that did not participated in the USAID MCHIP 
survey. 
 
Procedures for Archival Data 
Main Study Data Collection  
MCHIP Survey: Data collection was coordinated by the MCHIP maternal health team in 
Washington, D.C., during the months of January, February and March 2012. Contact information 
was compiled for an identified focal person in each of the 43 countries initially targeted by the 
survey. The contact list from 2011 was used and the individual’s continuing engagement with 
national activities was confirmed. Additional sources were contacted in an effort to ensure that 
there was an appropriate coordinator for the data-gathering activities in each country.  
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The coordinator for each country was sent an e-mail with anticipated dates and activities 
six weeks in advance of receiving the survey. He or she was instructed to contact national 
counterparts in the government as well as leading implementing partners. The country 
coordinator was given a timeline of pending requests and asked to arrange meetings with 
national consultative groups to ensure a national participatory process for the completion of the 
survey instruments. In most cases this was possible. Key stakeholders from government, 
ministries, MCHIP programs, other USAID bilateral programs, UN partners and other 
implementing agencies met to collect data and respond to the 46-item questionnaire and the 
scale-up map. In most cases, these consultative groups found it necessary to meet twice to ensure 
accuracy and completeness of responses.  
The questionnaire and scale-up maps were revised from the 2011 versions, based on 
responses, questions and feedback from the 2011 survey administration. Surveys were sent out 
via e-mail in English French and Spanish, and countries received copies of their 2011 surveys, 
which served as a starting point. Stakeholders met in-country to collect data and respond to the 
survey, and contacted the MCHIP maternal health team with questions. Responses were shared 
via e-mail in English, French and Spanish. Professional translators translated French and Spanish 
survey responses into English.  
WHO pharmaceutical sector country survey: Data collection in all 193 member states 
was conducted using a user-friendly electronic questionnaire that included comprehensive 
instruction manual and glossary. Countries were requested to enter the results from previous 
surveys and to provide centrally available information compiled data comes from international 
sources (e.g. the World Health Statistics), surveys conducted in the previous years and country 
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level information collected in 2011.  
Access to the dataset and permissions: Data set for both surveys are publicly available 
and can be found on the website of both organizations. An email will be sent to contact persons 
in both organizations to clarify any limitations to the use of data by the public for secondary 
analysis. Where relevant a data use agreement will be provided to clarify the details of the data 
elements needed, the responsibilities of the data provider and beneficiaries, and the boundaries of 
the data use.  
Instrumentation and operationalization of constructs: The main source of information 
for this study will be the limited dataset provided by the WHO pharmaceutical sector country 
profile, and USAID MCHIP survey data - which contains the identified information. It includes 
relevant sociodemographic characteristics, health-system characteristics and access indicators for 
each country. Information on the health system characteristics encompassed indicators in five 
domains – government/regulator, pharmaceutical supply, health facility, health service delivery, 
and information systems – as shown in table 3.1. 
The 46-item questionnaire included six core components: policy, training, drug 
distribution and logistics, national reporting of key maternal health indicators, programming, and 
challenges to and opportunities for scale-up.  
Operationalization of Variable 
Independent Variables  
Independent variables for the study included: Medicines Approved at National Level, 
Accessibility of Standard Treatment Guidelines, Policy Provision for Active management of 
third stage of labor (AMTSL), Good Governance, Procurement and Logistics, Equipment’s and 
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Supplies, Education/Training, Human Resources, Midwife/Skilled Birth Attendant Scope of 
practice, Health Spending, National Reporting on Selected Maternal Health Indicators. The 
USAID MCHIP survey instrument suggest that data was collected on these variables as outlined 
in Appendix 1: 
Dependent Variable 
The dependent variables included the availability, and accessibility of the three medicines 
in focus for this study. The USAID MCHIP survey gathered data on these variables as follows: 
Availability of medicines: The dataset included information on the availability of 
oxytocin, MgSO4, and Misoprostol in health facilities and central medical stores; and the 
frequency of oxytocin and MgSO4 stock outs in health facilities and central medical stores. 
Accessibility of Medicines: the dataset included information about home birth and ANC 
attendance. Specifically, data was collected on whether misoprostol is piloted for home births, 
misoprostol is scaled up for home births, and number of ANC visits. 
Affordability of Medicines: The dataset included information on whether these 
medicines are freely available to women or not. 
Data Analysis Plan 
Statistical Software.  
IBM SPSS Statistics 21 software was used to analyze data collected. The software was 
used to run both the descriptive and inferential analyses.  
Data Cleaning and Screening Procedures.  
Dataset contained about 41 variables needed for this analysis. As a first step, data was 
coded and inputted into SPSS. As next step, I produced frequency tables by variable to assess for 
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irregular entries. This step help me to check for coding errors, missing data, and outliers. 
Variables that have either outliers or more than 5% missing data were identified and excluded. 
Research Questions and Hypotheses 
The Study had five research questions: 
Research Question One 
1. Is there a significant association between governance and access to essential maternal 
health medicines in low and middle-income countries?  
Ho1: there is no significant association between governance and access to essential 
maternal health medicines in low and middle-income countries?  
Ha1: there is a significant association between the governance and access to essential 
maternal health medicines in low and middle-income countries?  
Research Question Two 
2. Is there a significant association between pharmaceutical supply and access to essential 
maternal health medicines in low and middle-income countries?  
Ho2: there is no significant association between pharmaceutical supply and access to 
essential maternal health medicines in low and middle-income countries?  
Ha2: there is a significant association between pharmaceutical supply and access to 
essential maternal health medicines in low and middle-income countries?  
Research Question Three 
3. Is there a significant association between the quality of health facility and access to 
essential maternal health medicines in low and middle-income countries?  
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Ho3: there is no significant association between the quality of health facility and access 
to essential maternal health medicines in low and middle-income countries?  
Ha3: there is a significant association between the quality of health facility and access to 
essential maternal health medicines in low and middle-income countries?  
Research Question Four 
4. Is there a significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Ho4: there is no significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Ha4: there is a significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Research Question Five 
5. Is there a significant relationship between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Ho5: there is no significant association between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Ha5: there is a significant association between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Statistical Analysis. 
Data Weighting.  
The primary study selected a disproportional sample of 37 countries from Asia, Africa 
and Middle East regardless of continent. Therefore, the preparation for data analysis will include 
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the data weighting to account for population size (no of countries) differentials between the 
continents.  
Testing for Multicollinearity.  
Before running the full analysis, I tested for multicollinearity to ascertain the 
independence of independent variables from each other. Forthofer, Lee, and Hernandez (2007) 
defined multicollinearity as a significant correlation between independent variables that can 
negatively affect the regression estimates by inflating the variance and standard errors. 
Multicollinearity occurs when an independent variable is a duplicate of another variable or is a 
redundant variable that measures the same thing. The analysis included a pairwise correlation 
analysis that correlated independent variables with each other in a bivariate correlation matrix. 
Any bivariate correlation equal or above .80 was considered an indication of a potential 
collinearity between two variables (Field, 2013).  
I also calculated the tolerance and variance inflation factor (VIF). Field (2013) defined 
Tolerance as the proportion of variance in the independent variable not attributable to the other 
independent variable: 1-R 2. The higher the tolerance, the lower the risk of multicollinearity. A 
tolerance of .10 or less is considered problematic. Likewise, the VIF reflects an inflation of the 
standard error due to multicollinearity: 1/ (1-R2). A VIF of 10 or more is considered problematic 
(Field, 2013; Forthofer et al., 2007).  
Checking for Outliers.  
I checked for the presence of outliers on originally numerical variables. Field (2013) 
defined outliers as values that are either extremely high or extremely low in the data (Field, 
2013). They have the potential to skew the data in one direction or the other and bias the 
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statistics. I will use the descriptive analysis function of SPSS to compare the mean and trimmed 
mean – mean without the 5% lowest and highest values – to see if there is a considerable 
difference. Besides, Z scores were created to identify outliers as all values with Z scores above 
3.29. Furthermore, a graphic presentation using histograms and boxplots was used to spot the 
outliers.  
Descriptive Analysis.  
The first step was to compute a total score for all items representing each variable (in 
table 3.1) and set cut-off score for variable categories. Then convert each variable into 
dichotomous variable (e.g. Highly available, Poorly available; highly accessible, poorly 
accessibility; highly affordable, poorly affordable).  
The second step of the descriptive analysis included a chi-square test to analyze the 
proportion of countries by variable category and estimate the standard deviations. The 
comparison also focused on comparing each variable category with sociodemographic 
characteristics, and each independent variable. A p-value < .05 was considered statistically 
significant. The variables achieving a p-value < .05 indicated the characteristics of difference 
between the two groups of countries. These two analyses will help to identify the independent 
variable categories with high access.  
Inferential Analysis.  
For the inferential analysis, applied the logistic regression in two steps to assess the 
association between health system variables and access to focus medicines.  
First step or Model 1. included a bivariate analysis of the crude association between 
each of the 6 dimensions and 16 health system variables (table 3.1) and two control variables 
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(sociodemographic variables.) and high access to medicines (dependent variable). The results 
was presented as crude OR, 95% CI, and p-value.  
Second step or Model 2. included a multivariate analysis of the adjusted association 
between health system variables with p< .05 identified during the bivariate analysis and high 
access to medicines (dependent variable). A hierarchical order of factors to be included in the 
first iteration was the variables of governance/regulation. The second iteration included the 
variables of health facility. The third iteration included variables of health service delivery. The 
forth iteration included variables of pharmaceutical supply. The fifth iteration included variables 
of data collection/information systems; and The sixth iteration included variables of health 
financing. The multivariate adjusted logistic regression analysis was controlled for confounders 
that have a p< .05 in the bivariate analysis of their association with high access to medicines. The 
results are represented as the Adjusted OR, 95% CI, and p-value.  
 
Threats to Validity 
External Validity: There is a threat to external validity when the findings are 
erroneously generalized to individuals who do not have the study participants’ characteristics, 
places that do not have the study setting characteristics, and different past or future situations 
(Creswell, 2013). The primary study minimized the threats to external validity by ensuring data 
was collected and confirmed with relevant stakeholders within each country. This helped to 
ensure the representativeness of the study participants to the target population. Besides, this 
study will restrict the generalization of its findings and claims to similar population groups and 
settings to enhance its external validity (Creswell, 2013).  
Internal validity: Creswell (2013) observed that threats to internal validity include the 
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procedures, treatments, and participants’ characteristics that may restrict the researcher’s ability 
to draw meaningful conclusions. In this study, the threats to internal validity were limited 
because of the use of secondary data. Besides, the random selection of participants in the primary 
study minimized the selection bias. Furthermore, the cross-sectional survey design with no 
experiment did not allow for the effect of history, maturation, regression, mortality, diffusion of 
treatment, testing, instrumentation, and selection-maturation interaction.  
Construct validity: Creswell (2013) reported that threats to construct validity occur 
when variable definitions and measures are inadequate. This study maintained the same 
definitions and measures of variables used in previous studies of ANC utilization and 
compliance (Joshi et al., 2014; Mugo et al., 2015; Trinh et al., 2007; Tsegay et al., 2013).  
Statistical conclusion validity: The threat to statistical conclusion validity occur when 
the study findings are not accurate because of insufficient statistical power or the violation of key 
assumptions (Creswell, 2013). In this study, I used a sufficient sample of all 37 resource poor 
countries with a maternal health program that participated in the MCIP survey so that they 
achieve a computed power of .80 or more on all independent variables.  
Besides, I ensured that the study met the assumptions required for a logistic regression 
analysis. First, the dependent variable – Access to medicines – was transformed into a 
dichotomous variable with two categories: High access and poor access based on z-scores 
computed for all measures in each variable category. Second, I assigned the code 1 to the 
category of ‘high access’ as the desired outcome. Third, only the variables with p< .05 on 
bivariate analysis were included in multivariate analysis through a hierarchical stepwise method. 
Fourth, I tested for multicollinearity to ensure the independent variables are independent of each 
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other. Fifth, I assessed for outliers and missing data and use multiple imputations to replace the 
missing data. Last, the study included an adequate sample size and the minimum number of 
cases per variable category was 18.  
Ethical Procedures  
To ensure the protection of the study participants’ rights, I have taken the web-based 
ethics training of the National Institutes of Health (NIH) Office of Extramural Research. The 
course intended to raise the awareness of researchers working with human subjects regarding 
their obligations towards the rights and welfare of human subjects in the conduct of research. 
The NIH certificate of completion is in Appendix B.  
Protection of Participants’ Rights  
This study used secondary data that have the advantage of enhancing the participants’ 
privacy as I did not interact directly with the study participants. In addition, the limited dataset 
did not include personal identifiers to prevent linking the data to the study participants. 
Furthermore, the Walden University IRB approved this study to ensure that it fully meets the 
required ethical standards.  
Data Protection  
The limited dataset was stored on a password-protected computer with a backup on a 
password-protected hard drive. I will keep the data for 5 years after the end of the study and 
destroy it using appropriate. The results of this study were aggregated to protect the privacy of 
the study participants. I disseminated the results to WHO, USAID MCHIP, in national and 
international conferences, and through peer-reviewed journals.  
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Summary 
This study was a quantitative cross-sectional survey using secondary data collected by the 
WHO pharmaceutical country survey and USAID MCHIP survey. Walden University IRB 
approved the study after verifying that it met the required ethical standards.  
The sample included 37 countries that participated in the USAID 2012 MCHIP survey 
The dependent variable access to essential maternal health medicines defined by availability, 
affordability and accessibility of essential maternal health medicines.  
The independent variables included measures such as if medicines are approved at 
National Level, Accessibility of Standard Treatment Guidelines, Policy Provision for Active 
management of third stage of labor (AMTSL), Good Governance, Procurement and Logistics, 
Equipment’s and Supplies, Education/Training, Human Resources, Midwife/Skilled Birth 
Attendant Scope of practice, Health Spending, National Reporting on Selected Maternal Health 
Indicators. Data was analyzed using the IBM SPSS Statistical software version 21. It included a 
descriptive analysis of each country’s characteristics as well as bivariate and multivariate logistic 
regressions of the health system characteristics that best predict access to essential maternal 
health medicines. Chapter 4 that follows will describes the secondary data analysis and presents 
its results.  
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Section 3: Results 
Introduction 
The purpose of this quantitative cross-sectional survey using secondary data analysis was 
to investigate the association between health-system characteristics and access to maternal health 
medicines. The study participants included 37 low and middle-income countries who participated 
in USAID MCHIP and WHO pharmaceutical 2011/2012 survey. I used the IBM SPSS Statistics 
21 software to answer the questions and test the hypotheses listed below: 
Question 1: Is there a significant association between governance and access to essential 
maternal health medicines in low and middle-income countries?  
Ho1: there is no significant association between governance and access to essential 
maternal health medicines in low and middle-income countries?  
Ha1: there is a significant association between the governance and access to essential 
maternal health medicines in low and middle-income countries?  
Question 2: Is there a significant association between pharmaceutical supply and access 
to essential maternal health medicines in low and middle-income countries?  
Ho2: there is no significant association between pharmaceutical supply and access to 
essential maternal health medicines in low and middle-income countries?  
Ha2: there is a significant association between pharmaceutical supply and access to 
essential maternal health medicines in low and middle-income countries?  
Question 3: Is there a significant association between the quality of health facility and 
access to essential maternal health medicines in low and middle-income countries? 
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Ho3: there is no significant association between the quality of health facility and access 
to essential maternal health medicines in low and middle-income countries?  
Ha3: there is a significant association between the quality of health facility and access to 
essential maternal health medicines in low and middle-income countries?  
Question 4: Is there a significant association between quality of service delivery and 
access to essential maternal health medicines in low and middle-income countries?  
Ho4: there is no significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Ha4: there is a significant association between quality of service delivery and access to 
essential maternal health medicines in low and middle-income countries?  
Question 5: Is there a significant relationship between health financing and access to 
essential maternal health medicines in low and middle-income countries?  
Ho5: there is no significant association between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
Ha5: there is a significant association between health financing and access to essential 
maternal health medicines in low and middle-income countries?  
 
Data Collection 
Data set for both surveys are publicly available and can be found on the website of 
WHO and USAID MCHIP. There was no discrepancy between the plan presented in Chapter 3 
and the actual data collection. 
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Primary data for the MCHIP survey was coordinated by the MCHIP maternal health team 
in Washington, D.C., during the months of January, February and March 2012. Contact 
information was compiled for an identified focal person in each of the 43 countries initially 
targeted by the survey. An identified coordinator for each country was sent an e-mail with 
anticipated dates and activities six weeks in advance of receiving the survey. He or she was 
instructed to contact national counterparts in the government as well as leading implementing 
partners. The country coordinator was given a timeline of pending requests and asked to arrange 
meetings with national consultative groups to ensure a national participatory process for the 
completion of the survey instruments. In most cases this was possible. Key stakeholders from 
government, ministries, MCHIP programs, other USAID bilateral programs, UN partners and 
other implementing agencies met to collect data and respond to the 46-item questionnaire and the 
scale-up map. In most cases, these consultative groups found it necessary to meet twice to ensure 
accuracy and completeness of responses. 
The WHO pharmaceutical country survey data was collected from all 193 member states 
using a user-friendly electronic questionnaire that included comprehensive instruction manual 
and glossary. Countries were requested to enter the results from previous surveys and to provide 
centrally available information compiled data comes from international sources (e.g. the World 
Health Statistics), surveys conducted in the previous years and country level information 
collected in 2011.  
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Inclusion and Exclusion Criteria 
The original MCHIP survey dataset included records of 37 countries from Africa, Asia 
and the Americas; while those of WHO country surveys included records for 193 member 
countries. The records were assessed for eligibility based on the inclusion and exclusion criteria. 
Countries were included if they participated in the USAIDS MCHIP survey. They were excluded 
if they did not participate in the MCHIP survey. 
Review of Statistical Assumptions 
The study analysis included standard multiple regressions on one outcome variable 
(Access to live-saving maternal health medicines) and six independent variables (Strength of 
health system governance, pharmaceutical procurement and distribution, quality of health 
services and facilities, health care financing, and reporting of relevant maternal health medicine 
indicators). Responses to forty-four numeric and string question items that best represented these 
variables were collected and grouped to form composite variables for the regression analysis. I 
reviewed the key assumptions of logistic regression analysis, in particular, the magnitude of 
missing data, presence of multi-collinearity and outliers, and the compliance with a minimum of 
10 cases per variable category. 
Outliers. Using Z-score method to identify outliers, analysis showed that data were 
positively skewed in four numeric indicators (number of hospital beds per 10,000; pharmacist 
per 10,000pop; and physicians per 10,000 population and Nurses and midwives per 10,000 
population) with skewness ranging of 4.148, 3.154, 4.891, 2.910 respectively. To make data 
normally distributed and suitable for further analysis, I applied a two-step process. Data were 
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first ranked using SPSS transform function. They were then transformed and computed to form 
new variables using SPSS Transform and IDF normal function.  
Missing data. The first part of the missing data analysis showed that 17 of the 44 
indicators for the independent and dependent variables included in the study had some missing 
data. The top five indicators were: public insurance coverage for medicines on EML (43.2%), 
Access to essential Medicines as part of fulfilment of the right to health (43.2%), Total health 
expenditure as percent of GDP (37.8%), availability of national guidelines for good distribution 
practices (37.8%), and presence of public sector procurement policies (35.1%).  
 
Figure 2. Summary of missing data in the study database. Generated from SPSS multiple 
imputation analysis of missing data patterns. 
High rates of missing data can introduce bias and compromise the validity of the study 
findings. Analysis of missing value patterns suggested some monolithic pattern of missing values 
across some variables. Multiple imputations, one of the most recommended missing data 
handling techniques, were used to replace the missing values with five imputations based on the 
predictive values derived from the observed data (Sterne et al., 2009). 
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Multicollinearity. Another test was a bivariate correlation analysis of the 12 independent 
variables in SPSS using the Pearson correlation coefficient. The results showed no value of the 
Pearson correlation coefficient equal or above .80, confirming that there was no multicollinearity 
between the variables of interest. All the correlation coefficients were below .60. The second test 
was the collinearity diagnostics in linear regression that examined the tolerance rate and variance 
inflation factor (VIF) (Field, 2013). The results found no tolerance rate below .10 or VIF above 
10. All the tolerance values were above .70 and VIF below two, indicating that there was no 
multicollinearity. 
Sample Size and Minimum Number of Cases in Each Variable Category. 
As a rule of thumb, each category of the independent variables included in logistic 
regression analysis must have a minimum of 10 cases (Vittinghoff & McCulloch, 2007). In that 
regard, the total sample of 37 was large enough to achieve sufficient statistical power. Some 
categories of the independent variables were combined to satisfy the rule of 10. The lowest cell 
count was 27 cases. All the other categories had more than 27 cases. 
Variable Categorization and Coding 
The analysis included one outcome and six independent variables. Responses to forty-
four numeric and string question items that best represented these variables were collected and 
combined to form composite dichotomous variables for the regression analysis.  
The outcome variable, Access to Medicines had three variables (coded 1. Yes, 2. No): 
availability of medicines, affordability of medicines, accessibility of medicines. Countries with 
less than 50% of the combined scores were assumed to have poor access (coded: 0,) while those 
with above 50% of combined score, good access (desired outcome, coded 1).  
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Similar procedures were used to organize the six independent variables. Strength of 
Health System Governance (coded 1 strong health system governance, 2. Weak health system 
governance) comprised of three items: medicine is approved at national level, guidelines for 
treatment are available, access to medicines and technologies are recognized as part of the right 
to health. Health system procurement, distribution and supply variable (coded, 1. Strong, 2. 
Weak) comprised of two items: medicines procurement system, medicines distribution and 
supply system. Quality of health facility variable (coded 1. High quality, 2. Poor quality) had one 
item: Number of hospital beds per 1000 population. Similarly, the quality of health services 
variable (coded 1. High quality, 2. Poor quality) had three items (adequacy of human resources 
for health, comprehensiveness or education and trainings for human resources for health, 
Midwife and Birth attendants scope of practice. Health system financing (coded 1. Robust 2. Not 
robust) had three items: Total health expenditure as % of GDP, Total Pharmaceutical, 
expenditure as % of health expenditure, private health expenditure as % of total health 
expenditure. Finally, the sixed variable – reporting of key maternal health medicines (coded 1. 
Strong reporting and 2. reporting had a single item: national reporting on key maternal medicines 
indicators  
Descriptive Analysis 
About 53% of countries enrolled in the study reported relatively good access to essential 
maternal health medicines compared to 47% that reported poor access – based on three 
indicators: availability, affordability, and accessibility of essential maternal health medicines. 
Medicines were often (75% of the time) available in only 24% of countries, affordable in 56% of 
80 
 
 
 
countries and accessible in 13.5% of countries. Oxytocin was more readily available (75% of the 
time) in 44% of countries compared with MgSO4 in 37% of countries. 
Regarding health systems governance, more countries (61.7%) recognize access to 
medicines as a right to health in their constitution compared with those that had maternal health 
medicines on their EML (52.8%) and had guidelines treatment (49.3%). However, amongst all 
three indicators for strength of health system governance, availability of medicines on the EML 
seemed to have a statistically significant relationship with access to medicines (p<0.001).  
Countries seemed to have better medicine procurement systems than distribution systems. 
More countries (62%) had strong procurement systems than they did strong distribution systems 
(and 44% respectively). Independently cross-tabbed, neither of these indicators showed 
statistically significant association with the outcome variable. In terms of quality of health 
facilities, only 24% of countries reported relatively substantial infrastructures for health and this 
indicator had a statistically significant association with access to essential maternal health 
medicines (p <0.001).  
Results differed slightly with indicators for quality of health services. Comparatively, 
their appeared to be the most gap in midwives and birth attendants scope of practice among 
countries. Nearly half (45%) of countries reported less comprehensive education and trainings 
for human resources for health while a little more than half (59% and 67% respectively) reported 
relatively less adequate human resources for health and narrow scope of practice for midwives 
and birth attendants. Except for education and training, other indicators for quality of health 
services showed statistically significant associations with the outcome variable. Few countries 
(14% and 35% respectively) appeared to have robust health system financing and report key 
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maternal health medicines indicators. These indicators showed statistically significant 
association with access to essential maternal health medicines. 
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Table 4 
 
Background Characteristics of the Countries 
Variables Characteristics 
All 
countries 
Yes 
<50% 
No 
>50% 
Chi-
Square 
P-
value 
  n (%) n (%) n (%)   
Health System 
Governance 
Medicines Approved at 
National Level 
36(100) 19(53) 17(47)   
 
Availability of Standard 
Treatment guidelines 
37(100) 18(49) 19(50) 26.260 0.000 
 
Access to Medicine 
recognized as right to 
Health in Constitution 
37(100) 23(62) 14(38)   
Medicine 
Procurement, 
Distribution and 
supply System  
Strong Medicine 
Procurement System 
37(100) 
 
23(62) 
14(38)   
 
Strong Medicine 
Distribution &Supply 
System 
37(100) 16(44) 21(54)   
Quality of Health 
facilities 
Have Substantial 
Infrastructure. 
37(100) 24(65) 13(34) 14.300 0.000 
Quality of Health 
Services 
Human resources for 
Health have 
Comprehensive 
Education and Training 
37(100) 20(54) 17(45) 5.896 0.015 
 
Human Resources for 
Health are relatively 
substantial 
37(100) 15(41) 22(59)   
 
Midwives/Birth 
Attendants have broad 
Scope of Practice 
37(100) 12(33) 25(67) 4.434 0.035 
Robustness of Health 
Financing 
Health and 
pharmaceutical 
expenditure 
37(100) 5(14) 32(85) 38.068 0.000 
National Reporting 
of Key Maternal 
Health Medicine 
Indicators 
Strong National 
Reporting of Key 
Maternal Health 
Medicine Indicators  
37(100) 12(35) 25(65) 8.680 0.003 
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Statistical Analysis Findings by Research Questions and Hypotheses 
The analysis report below includes the outcomes of bivariate and logistic regression 
analyses, based on a sample of 37 resource poor countries in Africa, Asia, and America who met 
the inclusion criteria. The first step was a bivariate (Chi-square) analysis of the association 
between six independent variables (Health system Governance, medicine procurement, 
distribution and supply, quality of health facilities, quality of health services, health financing 
and data reporting for key maternal health medicines.) and Access to essential maternal health 
medicines. Findings showed that all the independent variables, with the exception of quality of 
health services had a statistically significant association with access to maternal health medicines 
and achieved a p-value < .05. The second step included a multiple logistic regression analysis to 
test which of the five independent variables that had a statistically significant association with 
the outcome variable and a p-value < .05. significantly predicted access to essential maternal 
health medicines. The results of the regression indicated that three predictors explained 27% of 
the variance (R2 =.266, F(5,162)=13.12, p<.01). It was found that the strength of a country’s 
medicine procurement, distribution, and supply system significantly predicted access to essential 
maternal health medicines (β= -.41, p<.001), as did robustness or health system financing (β= -
.51, p<.001), and quality of health facilities (β= -.34, p<.05).  
 
Research question 1. The first question was stated as follows: Can access to live-saving 
maternal health medicines be predicted based on the strength of a country’s health system 
governance?  
Ho1: Access to essential maternal health medicines cannot be predicted based on the 
strength of a country’s health system governance?  
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Ha1: Access to essential maternal health medicines can be predicted based on the 
strength of a country’s health system governance? 
A chi-square test of independence was performed to examine the relation between 
strength of health system governance and access to live-saving maternal health medicines. The 
vast majority (71.8%) of countries enrolled in the study had weak health system governance as 
compared to 28.2% with strong health system governance. 
The standardized deviations to measure the magnitude of the difference between 
observed and expected values on women’s access to essential maternal health medicines by the 
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) 
showed that stronger health system governance had a negative deviation towards poor access to 
essential maternal health medicines. The inverse direction was observed for relatively weaker 
health system governance (table 6). A negative standardized deviation indicates that the observed 
values are lower than expected and a positive standardized deviation that the observed values are 
higher than expected. More countries (28%) with weaker health system governance had poor 
access to essential maternal health medicines compared with those with strong health system 
governance (11%).  
Table 5 
 
Standardized Deviations of Health System Governance by Access to Maternal Health Medicines 
  Access to Maternal Health Medicines 
  Good Poor 
Health 
Systems 
Governance 
Strong +1.6 -3.3 
Weak -1.0 +2.1 
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The bivariate analysis showed a statistically significant association between health 
system governance and access to essential maternal health medicines χ(1) = 18.999, OR = 
1.368, CI [ 1.239, 1.150], p = .000. This finding may suggest that women in countries with 
stronger health system governance were more likely to have better access to maternal health 
medicines than those in countries with weaker health system governance. However, a 
multivariate analysis that followed did not retain the statistically significant association 
between the strength of health system governance and access to essential maternal health 
medicines (β= -.160, t = -1.351, CI [ -0.394, 0.074], p =.178). Therefore, I accept the null 
hypothesis and conclude that access to essential maternal health medicines cannot be predicted 
based on the strength of a country’s health system governance. 
Research question 2. The second question was stated as follows: Can access to essential 
maternal health medicines be predicted based on the strength of a country’s medicine 
procurement, distribution, and supply system?  
Ho2: Access to essential maternal health medicines cannot be predicted based on the 
strength of a country’s medicine procurement, distribution, and supply system?  
Ha2: Access to essential maternal health medicines can be predicted based on the 
strength of a country’s medicine procurement, distribution, and supply system? 
A chi-square test of independence was performed to examine the relation between 
strength of Medicine procurement, distribution and supply system and access to essential 
maternal health medicines. The vast majority (64.3%) of countries enrolled in the study had 
weak medicine procurement, distribution and supply system compared to 35.7% with strong 
medicine procurement, distribution and supply system. 
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The standardized deviations to measure the magnitude of the difference between 
observed and expected values on women’s access to essential maternal health medicines by the 
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) 
showed that stronger medicine procurement, distribution and supply system had a negative 
deviation towards poor access to essential maternal health medicines (table 6). A negative 
standardized deviation indicates that the observed values are lower than expected and a positive 
standardized deviation that the observed values are higher than expected.  
More countries (24.8%) with weaker medicine procurement, distribution and supply had 
poor access to essential maternal health medicines compared with those with strong Medicine 
procurement, distribution and supply system (8.1%).  
Table 6 
 
Standardized Deviations of Medicine procurement, distribution and supply by Access to 
Maternal Health Medicines 
  Access to Maternal Health Medicines 
  Good Poor 
Medicine 
procurement, 
distribution and 
supply 
Strong +1.0 -2.1 
Weak -.8 1.6 
 
The bivariate analysis showed a statistically significant association between medicine 
procurement, distribution and supply system and access to essential maternal health medicines 
χ(1) = 8.676, OR = 3.740, CI [ 1.486, 9.411], p = .003.  
A multivariate analysis that followed retained the statistical significant association 
between medicine procurement, distribution and supply system of a country and access to 
essential maternal health medicines (β= -.411, t = - 3.641, CI [ - 0.634, -.188], p <0.001). These 
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findings suggest that women in countries with stronger health medicine procurement, distribution 
and supply systems were more than 3 times more likely to have better access to maternal health 
medicines than those in countries with weaker medicine procurement, distribution and supply 
system. Therefore, I reject the null hypothesis and conclude that access to essential maternal 
health medicines can be predicted based on the strength of a country’s medicine procurement, 
distribution and supply system. 
 
Research question 3. The third question was stated as follows: Can access to essential 
maternal health medicines be predicted based on the quality of health facilities in a country?  
Ho3: Access to essential maternal health medicines cannot be predicted based on the 
quality of health facilities in a country  
Ha3: Access to essential maternal health medicines can be predicted based on the quality 
of health facilities in a country.  
A chi-square test of independence was performed to examine the relation between quality 
of health facility and access to live-saving maternal health medicines. The vast majority (65.6%) 
of countries enrolled in the study had relatively good quality health facilities compared to 34.4% 
with poor quality. 
The standardized deviations to measure the magnitude of the difference between 
observed and expected values on women’s access to essential maternal health medicines by the 
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) 
showed that countries with good quality health facilities had a negative deviation towards poor 
access to essential maternal health medicines (table 6). The reverse was the case for countries 
with poor quality health facilities. A negative standardized deviation indicates that the observed 
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values are lower than expected and a positive standardized deviation that the observed values are 
higher than expected.  
More countries (33.7%) with poor quality health facilities had poor access to essential 
maternal health medicines compared with those with higher quality health facilities (11.7%).  
 
Table 7 
 
Standardized Deviations of Quality of Health Facilities by Access to Maternal Health Medicines 
  Access to Maternal Health Medicines 
  Good Poor 
Quality of 
Health Facilities 
Strong +1.0 -2.0 
Weak -1.3 +2.8 
 
 
The bivariate analysis showed a statistically significant association between quality of 
health facilities and access to essential maternal health medicines χ (1) = 14.600, OR = 3.781, CI 
[ 1.849, 7.733], p <0.001. A multivariate analysis that followed retained the statistical significant 
association between the quality of health facilities in a country and access to essential maternal 
health medicines (β= -.342, t = - 3.055, CI [ - 0.563, -.121], p <0.05). These findings suggest that 
women in countries with higher quality health facilities were more likely to have better access to 
maternal health medicines than those in countries with poor quality of health facilities. 
Therefore, I reject the null hypothesis and conclude that access to essential maternal health 
medicines can be predicted based on the quality of health facilities in a country. 
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Research question 4. The Forth question was stated as follows: Can access to essential 
maternal health medicines be predicted based on the quality of health services provided in a 
country?  
Ho4: Access to essential maternal health medicines cannot be predicted based on the 
quality of health services provided in a country 
Ha4: Access to essential maternal health medicines can be predicted based on the quality 
of health services provided in a country.  
A chi-square test of independence was performed to examine the relation between quality 
of health services and access to essential maternal health medicines. The vast majority (77.9%) 
of countries enrolled in the study reported relatively poor quality health services compared to 
22.1% with poor quality.  
The standardized deviations to measure the magnitude of the difference between 
observed and expected values on women’s access to essential maternal health medicines by the 
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) was 
not significant (< +- 1.95).  
Table 8 
 
Standardized Deviations of Quality of Health Services by Access to Maternal Health Medicines 
  Access to Maternal Health Medicines 
  Good Poor 
Quality of 
Health Services 
Strong +0.2 -0.5 
Weak -0.1 +0.3 
 
The bivariate analysis did not show a statistically significant association between quality 
of health services and access to essential maternal health medicines χ (1) = 0.462, OR = 1.389, 
CI [ 0.537, 3.598], p = .497. Therefore, I accept the null hypothesis and conclude that women’s 
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access to essential maternal health medicines cannot be predicted based on the quality of health 
services.  
Research question 5. The fifth question was stated as follows: Can access to essential 
maternal health medicines be predicted based on the robustness of a country’s health financing?  
Ho5: Access to essential maternal health medicines cannot be predicted based on the 
robustness of a country’s health financing? 
Ha5: Access to essential maternal health medicines can be predicted based on the 
robustness of a country’s health financing.  
A chi-square test was performed to examine the relation between health care financing 
and access to essential maternal health medicines. The vast majority (85.7%) of countries 
enrolled in the study had relatively robust health care financing compared to 14.3% with poor 
quality. 
The standardized deviations to measure the magnitude of the difference between 
observed and expected values on women’s access to essential maternal health medicines by the 
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) 
showed that countries with more robust health financing had a negative deviation towards poor 
access to essential maternal health medicines (table 8) than those with less robust health 
financing. The reverse was the case for countries with less robust health care financing. A 
negative standardized deviation indicates that the observed values are lower than expected and a 
positive standardized deviation that the observed values are higher than expected.  
More countries (60.0%) with less robust health care financing reported poor access to 
essential maternal health medicines compared with those with more robust (12.2%).  
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Table 9 
 
Standardized Deviations of Health Care Financing by Access to Maternal Health Medicines 
  Access to Maternal Health Medicines 
  Good Poor 
Health 
Financing 
Robust +1.0 -2.1 
Less Robust 
 
-2.5 +5.1 
 
The bivariate analysis showed a statistically significant association between the 
robustness of health care financing and access to essential maternal health medicines χ(2) = 
38.068, OR = 10.773, CI [ 4.578, 25.352], p = .000. Women in countries with more robust health 
care financing were more likely to have better access to maternal health medicines than those in 
countries with less robust health care financing. A multivariate analysis that followed retained 
the statistical significant association between the quality of health facilities in a country and 
access to essential maternal health medicines (β= -.514, t = - 4.993, CI [ - 0.720, - 0.309], p 
<0.001). These findings suggest that women in countries with more robust health financing were 
more likely to have better access to maternal health medicines than those in countries with less 
robust health financing. Therefore, I reject the null hypothesis and conclude that access to 
essential maternal health medicines can be predicted based on robustness of a country’s health 
financing.  
Research question 6. The Sixth question was stated as follows: Can access to essential 
maternal health medicines be predicted based on the strength of data reporting on key maternal 
health medicines indicators in a country?  
Ho6: Access to essential maternal health medicines cannot be predicted based on the 
strength of data reporting on key maternal health medicines indicators in a country 
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Ha6: Access to essential maternal health medicines can be predicted based on the 
strength of data reporting on key maternal health medicines indicators in a country. 
A chi-square test of independence was performed to examine the relation between health 
care financing and access to essential maternal health medicines. The vast majority (64.9%) of 
countries enrolled in the study had relatively weak reporting for key maternal health medicines 
indicators compared to 35.1% with stronger reporting. 
The standardized deviations to measure the magnitude of the difference between 
observed and expected values on women’s access to essential maternal health medicines by the 
strength of a country’s health system governance (Spiegel, Schiller, and Srinivasan, 2009) 
showed that countries with stronger reporting had a negative deviation towards poor access to 
essential maternal health medicines (table 8) than those with weak reporting. A negative 
standardized deviation indicates that the observed values are lower than expected and a positive 
standardized deviation that the observed values are higher than expected.  
More countries (23.6%) with weak maternal health medicines indicator reporting 
mechanisms reported poor access to essential maternal health medicines compared with those 
with stronger mechanisms (7.7%).  
Table 10 
 
Standardized Deviations of National Reporting of Key Maternal Health Medicine Indicators by 
Access to Maternal Health Medicines 
  Access to Maternal Health Medicines 
  Good Poor 
National 
Reporting of 
MH Indicators 
Strong 
Reporting 
+1.0 -2.1 
Weak Reporting 
 
-0.7 +1.6 
 
12 
 
 
 
The bivariate analysis showed a statistically significant association between the national 
reporting of key maternal health medicine indicators and access to essential maternal health 
medicines χ(2) = 8.680, OR = 3.709, CI [ 1.482, 9.282], p = .003. Women in countries with 
better reporting of indicators were more likely to have better access to maternal health medicines 
than those in countries with weak reporting. 
However, a multivariate analysis that followed did not retain the statistically significant 
association between national reporting of key maternal health medicine indicators and access to 
essential maternal health medicines (β= -.0.047, t = -.394, CI [ -0.281, 0.487], p =.694). 
Therefore, I accept the null hypothesis and conclude that access to essential maternal health 
medicines cannot be predicted based on national reporting of key maternal health medicine 
indicators. 
Summary 
This study included 12 questions and 6 hypotheses investigating the association between 
health system characteristics and women’s access to essential maternal health medicines in 37 
low and middle-income countries. 
The analysis involved bivariate and multivariate analyses. Bivariate analyses showed that 
five of the six health system characteristics examined (strength of health system governance, 
strength of medicine procurement, distribution and supply system, quality of health facilities, 
robustness of health system financing, and national reporting of key maternal health medicine 
indicators) had a statistically significant association with women’s access to essential maternal 
health medicines with a p-value < .05. quality of health services had no statistically significant 
association with women’s access to essential maternal health medicines p > .05. 
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Multivariate analyses included the five independent variables above, which had a p-value 
<.05. The second step included a multiple logistic regression analysis to test of the five 
independent that had a statistically significant association with the outcome variable and a p-
value < .05. significantly predicted access to essential maternal health medicines. The results of 
the regression indicated that three predictors explained 27% of the variance (R2 =.266, 
F(5,162)=13.12, p<.01). It was found that the strength of a country’s medicine procurement, 
distribution, and supply system significantly predicted access to essential maternal health 
medicines (β= -.41, p<.001), as did robustness or health system financing (β= -.51, p<.001), and 
quality of health facilities (β= -.34, p<.05). 
I conclude that the strength of a country’s medicine procurement, distribution, and supply 
system medicines, the robustness of health system financing and quality of health facilities (β= -
.34, p<.05). significantly predicted access to essential maternal health medicines in low and 
middle-income countries. 
Chapter 5 includes a discussion of health system characteristics that have shown a 
statistically significant association with access to maternal health medicines in 37 low and 
middle-income countries and a comparison of these findings with previous studies. It presents 
the study limitations, its implications for positive social change, and recommendations for 
research, policy and practice. 
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Section 4: Application to Professional Practice and Implications for Social Change  
Introduction 
This study was a quantitative cross-sectional survey using secondary data from the 
USAID MCHIP and WHO pharmaceutical 2011/2012 survey. It examined the association 
between health system characteristics and women’s access to essential maternal health 
medicines. Postpartum hemorrhage (PPH), pre-eclampsia and eclampsia together account for 
nearly half (41%) of the 289,000 pregnancy-related deaths worldwide (WHO, et al., 2014). 
Access to oxytocin, misoprostol and magnesium sulfate (herein referred to as essential maternal 
health medicines) - three medicines that prevent and treat these pregnancy-related complications 
(Fujioka, & Smith, 2011), has remained suboptimal, in particular among women in developing 
countries (USAID, Landscape Analysis: Postpartum Hemorrhage Solutions, unpublished data, 
2012). The suboptimal access to these medicines may explain in part the persisting high maternal 
mortality rates in developing countries. This study was conducted to identify the health system 
determinants of women’s access to essential maternal health medicines in developing countries.  
The data analysis included bivariate and multivariate analyses that showed that the 
strength of a country’s medicine procurement, distribution, and supply system, robustness of 
health system financing, and quality of health facilities had a statically significant association 
with women’s access to maternal health medicines. The findings showed that women in 
countries with stronger health system governance AOR = 1.368, 95% CI [ 1.239, 1.150], p < .01; 
stronger medicine procurement, distribution and supply system AOR = 3.740, 95% CI [ 1.486, 
9.411], p < .05; better quality of health facilities AOR = 3.781, 95% CI [ 1.849, 7.733], p <0.001; 
more robust health care financing AOR = 10.773, 95% CI [ 4.578, 25.352], p <0.01; better 
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reporting for maternal health medicines indicators AOR = 3.709, 95% CI [ 1.482, 9.282], p 
<0.01; were more likely to have better access to maternal health medicines. The quality of health 
services, had no statistically significant association with women’s access to maternal health 
medicines. 
Interpretation of the Findings 
Study Findings and Past Research 
Strength of health system governance and access to essential maternal health 
medicines. The study analysis showed that pregnant women living in countries with stronger 
health system governance were more likely to have better access to essential maternal health 
medicines. Although more countries (61.7%) recognize access to medicines as a right to health in 
their constitution compared with those that had maternal health medicines on their EML (52.8%) 
and had treatment guidelines (49.3%), availability of medicines on the EML seemed to be the 
only measure with statistically significant relationship with access to medicines (p<0.001). 
Observations regarding these three measures indicate a level of political will for reversing high 
maternal mortality rate in developing countries. Availability of essential maternal health 
medicines in EML also indicate a level of recognition for promoting rational use of essential 
maternal health medicines as per WHO recommendations (WHO 2004).  
This study supports findings from studies conducted by Ridge et al. (2010), Muldoon et 
al (2011), Smith et al., (2014), Tran & Bero (2015). Ridge et al., showed that a critical 
component for adequate access to and use of MgSO4 was the inclusion of MgSO4 in National 
Essential Medicines List (NEML), the availability of Standard Treatment Guidelines (STG) and 
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registration of medicines in the country for use in treatment of severe pre-eclampsia and 
eclampsia.  
Smith et al., found that countries that reported infrequent availability of misoprostol 
indicated a lack of a national policy supporting misoprostol as a principle cause. Similarly, Tran 
& Bero found that the first common facilitator of quality use of oxytocin egometrin and 
magnesium sulfate at the government policy level was that all three essential medicines were 
consistently listed on national EMLs.  
Medicines supply system. This study examined the association between the strength of a 
country’s medicine supply system and women’s access to essential maternal health medicines. 
The results showed, in a bivariate and multivariate analysis, that women in countries that had 
stronger medicines supply system had a higher likelihood of having access to essential maternal 
health medicines than those with weak medicines supply systems. Descriptive statistics for each 
measure of medicine supply system assessed (medicines procurement and medicines 
distribution) further showed that more countries had stronger medicines procurement system 
than they did medicines distribution systems, and countries with stronger distribution systems 
were more likely to have better access than those with stronger procurement systems.  
These findings are similar to Hopu, Ranganathan & Dodoo, 2011 assertions that countries 
lack essential medicines because of fragile supply systems and poor-quality products. Ridge, 
Bero & Hill (2010) found that poor availability of magnesium sulfate in Zambia reflected a 
limitation of the countries procurement system. Another similar observation made by Ridge et 
al., (2010) study is that procurement was based on presence of medicines in a country’s essential 
medicines list, and supply of medicines to health facilities depended on availability of medicines 
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in central medical stores – which aligns with findings from this study that found a significant 
relationship between medicines distribution systems and access to medicines. 
Findings from this study however differed from those of Haddad and Fourniew (1995) 
who found that in Zaire, s steady supply of medicines did not reverse a reduction in utilization. 
Similarly, Mwabu (1993) found that greater availability of medicines had a negative relationship 
with utilization of these medicines. These findings may be attributed to Ridge et al. (2010) 
observation that lack of demand by health professionals at the health center level negatively 
affected access to essential maternal health medicines.  
Quality of health facilities: The study examined the association between the quality of 
health facilities in a country and women’s access to essential maternal health medicines. 
Observations from the literature suggest that the concept of quality could be a difficult factor to 
capture in both cross-sectional and time-series analyses. Hence for the purpose of this study, a 
key indicator for quality used included number of hospital beds per 10,000 population. Findings 
of bivariate and multivariate analyses showed that women in countries with better quality health 
facilities had a higher likelihood of receiving essential maternal health medicines when needed.  
Findings from this study aligns with findings from studies carried out by Bitran, 1989, 
Yoda, 1989, Hutton, 2004; and James et al., 2006. These studies found that utilization was lower 
where quality of care was perceived to be lower. They also found that utilization ins smaller-
phased -in programs increased when combined with quality improvements. Also, Denton, et al. 
(1990) and Akin, et al. (1990) in their study in Nigeria found that facility conditions were 
significantly associated with service utilization. 
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However, findings from this study differed from those of Chalker (1995), Anis (1981), 
Chalker and Anis found that rural health post had reasonable good quality facilities but were not 
used. Denton et al., and Akin et al., in the same study mentioned earlier, noted that Machineries 
(x-ray machine, and laboratories) were not significantly associated with service utilization.  
Quality of health services provided in a country: The study examined the association 
between quality of health services and women’s access to maternal health medicines. Nearly half 
(45%) of countries reported less comprehensive education and trainings for human resources for 
health while a little more than half (59% and 67% respectively) reported relatively less adequate 
human resources for health and narrow scope of practice for midwives and birth attendants. 
Except for education and training, other indicators for quality of health services showed 
statistically significant associations with the outcome variable. However, the association between 
the quality of health services and access to maternal health medicines not statistically significant 
in bivariate analysis. 
These findings agree with findings from seven studies by Anis, (1981), Denton, et al. 
(1990) and Akin, et al. (1990), Javadi, and Bigdeli, (n.d) Heller (1982) and Ainstworth et al., 
(1993) Ridge et al. (2010); (Muldoon et al., 2011).  
Denton, et al. (1990) and Akin, et al. (1990) findings suggested that number of support 
personnel, nurses, and doctors per capita was not significantly associated with service utilization. 
Rouse (2008), Javadi, and Bigdeli, (n.d) found that service delivery affected how medicines can 
reach patients and the extent to which rational use are upheld. Heller (1982) and Ainstworth et 
al., (1993) also found that the association between the probability of being seen by a physician 
and service access was insignificant. Nurses, doctors and skilled attendant density were 
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associated with decreased mortality for infants (Muldoon et al., 2011). Ridge et al. (2010) found 
a lack of in-service training in the use of specific medication as a barrier to access to that 
medication.  
National health system financing: The study examined the association between the 
robustness of a countries health system financing and access to essential maternal health 
medicines and found that women in countries with more robust health system financing were 
more likely to have better access to these medicines. 
This study aligns with Javadi and Bigdeli, (n.d) who found that financing systems are a 
major bottle neck to access due to low affordability of medicines. Without national policies to 
give universal access to essential maternal health medicines. 
Study Findings and Ishikawa (Cause Effect) Model 
This study used the Ishikawa (cause effect) model that posits that multiple factors with 
dynamic processes influence a given outcome are varying levels. The model has been used to 
illustrate the relationship between a given outcome and all the factors that influence this 
outcome, and provide additional insight into the behavior of processes (Ishikawa, 1960).  
Ridge et al (2010) fishbone diagram advanced that barriers and facilitators to availability 
and use of maternal health medicines occur at different levels of a health system including 
regulatory, government, supply, procurement, distribution, health facility, and health 
professional levels. The 2010 model advanced that certain primary determinants lead to 
improved availability and use of essential maternal health medicines. 
This study examined health system building blocks as an intervention to improve 
availability, affordability and accessibility (access) of essential maternal health medicines (health 
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outcomes). Its findings support Ridge et al’s model. They showed that women living in countries 
with stronger health system governance, stronger medicine supply system, better quality of 
health facilities, more robust health care financing, and better reporting for maternal health 
medicines indicators were more likely to find maternal health medicines available, affordable 
and accessible when needed.  
Further, certain individual characteristics such as presence of medicines in a countries 
essential medicines list, midwives scope of practice, and strength of medicines distribution 
system played an important role in women’s access to maternal health medicines. In this regard, 
Ishikawa cause effect model was a useful model that guided the identification of the study 
variables, design of study questions and hypotheses, data analysis, and interpretation of findings. 
Limitations of the Study 
There were five limitations in this study. First, the study used a cross-sectional 
quantitative design with institutional level data collected at one point in time (Sedgwick, 2014). 
The cross-sectional quantitative nature of this study did not allow any causal inferences, nor 
explanatory dimensions to observations. 
Second, different measures of equity and economic status have been considered as 
predictors of access in developing countries (Wegstaff, 2000b; Filmer & Pritchett, 2001; Heller, 
1982; Dzator et al., 2004). Since this study was not a household survey, data was not collected at 
the household or population level. Consequently, the study missed out of demand side factors of 
a health system that potentially affect access. 
Factors like geographical location, age, hospital waiting time, time spent travelling to 
health facility, education or occupation, household consumption and literacy levels are important 
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factors that would have provided greater insights into the relationship between demand side 
dynamics of a countries health system and access to maternal health medicines. Other important 
aspects of health system determinants not covered in this study include aspects of market 
dynamics like procurement prices of medicines, monopoly of few pharmaceutical companies and 
small markets.  
Third, the self-reporting countries were at risk of social desirability bias by giving 
socially acceptable answers. Third, the observational nature of the study did not allow any cause-
and-effect analysis in the absence of variable manipulation. Forth, the cross-sectional nature of 
the study did not allow any sequencing of events between independent and dependent variables 
nor any trend analysis on the study outcome. 
Recommendations for Further Research 
This study was the first cross sectional study to examine the health system determinants 
of access to maternal health medicines in 37 low and middle-income countries. It has highlighted 
the important role of quality of health care facilities, public health financing and data collection 
and monitoring of maternal health medicines indicators with access to essential maternal health 
medicines. It has also pointed to some knowledge gaps and areas for further research.  
The cross-sectional quantitative nature of this study did not allow any causal inferences, 
nor explanatory dimensions to observations. A prospective study of access to essential maternal 
health medicines can help understand the sequencing of events and establish cause-and-effect 
relationships among independent variables. Furthermore, future studies should include other 
health system characteristics (independent variables) not measured in this study and should 
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include qualitative dimensions to foster more in-depth understanding of the intricate dynamics of 
access to maternal health medicines.  
The achievement of better access to maternal health medicines for woman in developing 
countries will depend on the effectiveness and level of implementation of innovative strategies 
specific to the context and realities of each country. Therefore, further studies are needed to 
identify the most effective strategies to strengthen health systems in developing countries – in 
other to improve women’s access to essential maternal health medicines.  
Implications  
Implications for Positive Social Change 
This study examined an important health issue affecting vulnerable women in developing 
countries where health disparities and social injustices are evident through the disproportional 
burden of maternal deaths (DHS Program, n.d.). Access to maternal health medicines has 
remained suboptimal in many developing countries despite government’s and international 
development efforts. Limited understanding of the drivers of access to these medicines in these 
countries may have contributed to the persisting inequalities in access to these medicines. 
This study will foster positive social change by generating knowledge on the predictors 
of access to live-saving maternal health medicines among women in resource-poor settings to 
help policy makers, health mangers, and service providers understand not only the barriers to 
access faced by this vulnerable population, but the comparative strength of each barrier in 
mitigating access to medicines.  
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The findings, if used appropriately, could guide the design of public health interventions 
aimed at improving access to essential maternal health medicines in resource poor settings, and 
reduce the southern - western gap in Maternal health outcomes. 
For these reasons, the dissemination of the study findings will target the Ministries of 
Public Health, International public health agencies, nongovernmental organizations (NGO’s), 
donors and research institutions. Local and international civil society advocates and experts will 
also be targeted through program, policy, and strategic meetings and conferences. Besides, the 
study will be published in peer-reviewed journals to further share its findings with the 
international community. 
Implications for Practice 
This study may play an important role in the design of interventions to improve 
availability, affordability and accessibility of maternal health medicines in developing 
countries. Its findings have pointed to three important areas of work: the quality of care, 
funding for public health, and data reporting for maternal health medicines indicators. While it 
is important to take be holistic in addressing health system barriers to access to medicines, 
ministries of health may consider prioritize programs based on their relative potentials to 
maximize impact, more so in this era of shrinking resources for public health.  
Financing for public health in these countries emerged as the stronger predictor of access 
to maternal health medicines. In this era of declining resources for public health, National and 
local level maternal health programs may want to consider thinking creatively on avenues to 
mobilize resources with the limited resources available. Exploring and establishing partnerships 
with the private sector and other individual sponsors may be a strategic direction to go in coming 
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years. could use the evidence generated in this study to identify health system factors limiting 
access to and use of maternal health medicines, and prioritize programs based on their relative 
potentials to maximize impact.  
The Ministry of Public Health should establish Maternal health medicines Quality 
Improvement programs (MHM-QIP) to ensure that women experience pregnancy related 
emergencies receive all the medicines they need for the well-being of the mother-baby pair. 
Like many developing countries (Lehmann, Dieleman, & Martineau, 2008), countries 
studied in this project suffer from the maldistribution of health professionals, limited scope of 
practice for few health professionals available, and inadequate health care facilities Therefore, 
the Ministry of Public Health should put in place a human resource policy that encourages the 
training and redistribution of roles and scope of practice for midwives and nurses. The efforts of 
government and its implementing partners should aim at getting and retaining trained midwives 
and nurses in every rural public health facility.  
Conclusion 
The persisting high maternal mortality in developing countries testifies to the prevailing 
social injustice in access to quality maternal health medicines in disadvantaged populations. This 
study was the first to examine the comparative relationship between health system characteristics 
and women’s access to three essential maternal health medicines across a wide range of 
developing countries. Its findings support the hypothesis that health system characteristics, in 
particular, health systems financing, procurement systems and quality of health facilities; can 
predict women’s access to essential maternal health medicines.  
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This new knowledge is useful to guide global health agencies and national health 
authorities in design of interventions, in particular, health financing advocacy, quality 
improvements in health care facilities and pharmaceutical supply infrastructure and process 
improvement. If successfully implemented, these interventions should help close the developed – 
developing country gap in maternal health outcomes. Further research is needed to understand 
the demand side drivers of poor access to maternal health medicines at household and 
institutional levels in developing countries. 
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Appendix 
Appendix 1: Variables and Data Source 
 Domain/Lev
el 
Variable Name Questionnaire Item Data Sources 
H
ea
lt
h
 s
y
st
em
 
  G
o
v
er
n
m
en
t/
R
eg
u
la
to
ry
 
Medicines Approved 
at National Level 
Oxytocin on EML for prevention and treatment 
of PE/E 
2012 NCHIP 
Survey database) 
Misoprostol on EML for prevention and 
treatment of PE/E 
NCHIP Survey 
Misoprostol on the EML  NCHIP Survey  
MgSO4 is national policy for treatment of PE/E NCHIP survey 
Diazapern is national policy for PE/E NCHIP Survey 
 
Accessibility of 
Standard Treatment 
Guidelines 
Standard treatment guideline translated into 
suitable local protocol  
WHO 
pharmaceutical 
country profile 
data 
Recommended treatment in national standard 
treatment guideline 
WHO 
pharmaceutical 
country profile 
data 
Policy Provision for 
Active management of 
third stage of labor 
(AMTSL) 
AMTSL is national policy NCHIP Survey 
AMTSL in service delivery guidelines NCHIP Survey 
 
 
Good Governance 
National good governance policy present? 
 
WHO 
pharmaceutical 
country profile 
data 
Access to essential medicines/technologies as 
part of the fulfillment of the right to health, 
recognized in the constitution or national 
legislation?  
WHO 
pharmaceutical 
country profile 
data 
    
Pharmaceuti
cal Supply 
System 
Procurement 
and Logistics 
Procurement procedure document in place WHO 
pharmaceutical 
country profile 
data 
Medicine supplied to health care facility 
 
WHO 
pharmaceutical 
country profile 
data 
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H
ea
lt
h
 F
ac
il
it
y
 
 
 
Equipment’s and 
Supplies 
Equipment and supplies available for diagnosis 
of complications and drug storage 
 
WHO 
pharmaceutical 
country profile 
data 
Equipment and supplies are available to 
administer medicine 
WHO 
pharmaceutical 
country profile 
data 
 
 
 
 
 
Education/Training 
Pre-service education curricula include AMTSL  
 
NCHIP Survey 
Current global management principles for PE/E 
included in in-service training courses 
 
NCHIP Survey 
AMTSL included in in-service training 
curricula 
 
NCHIP Survey 
Pre-service education curricula include current 
global management principles for PE/E  
 
NCHIP Survey 
Students assessed for competency in 
performance of AMTSL 
 
NCHIP Survey 
 Health providers aware medicine is first–line 
treatment 
 
 
H
ea
lt
h
 D
el
iv
er
y
 
 
 
Human 
Resources 
Physicians per 10,000 pop 
 
WHO 
pharmaceutical 
country profile 
data 
Number of hospital beds per 10,000 
 
WHO 
pharmaceutical 
country profile 
data 
Nurses and midwives per 10,000 pop 
 
WHO 
pharmaceutical 
country profile 
data 
Trained staff available to administer medicine WHO 
pharmaceutical 
country profile 
data 
 Midwives authorized to perform manual NCHIP Survey 
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Midwife/Skilled Birth 
Attendant Scope of 
practice 
removal of placenta 
 
Midwives authorized to perform AMTSL with 
oxytocin 
 
NCHIP Survey 
Midwives authorized to diagnose severe PE/E 
and administer MgSO4 
NCHIP Survey 
  
H
ea
lt
h
 F
in
an
ci
n
g
 
 
 
 
Health Spending 
Total health expenditure as % of Gross 
Domestic Product 
 
WHO 
pharmaceutical 
country profile 
data 
Private health expenditure as % of total health 
expenditure (% of total expenditure on health)  
WHO 
pharmaceutical 
country profile 
data 
Pharmaceutical expenditure as a % of Health 
Expenditure (% of total health expenditure) 
WHO 
pharmaceutical 
country profile 
data 
    
Data 
Collection 
and 
Reporting 
National Reporting on 
Selected Maternal 
Health Indicators 
AMSTL included in national HMIS NCHIP Survey 
Indicator to monitor severe PE/E included in 
national HMIS 
NCHIP Survey 
     
A
cc
es
s 
to
 M
H
L
S
M
 M
ed
ic
in
e
 
 
 
 
Availability 
Availability of 
Oxytocin 
 
Availability of Oxytocin in health facility 
 
NCHIP Survey  
 Availability of Oxytocin in regional/central 
medical stores 
NCHIP Survey 
Availability of MgSo4  Availability of MgSo4 in health facilities NCHIP Survey 
 Availability of MgSO4 in Central Medical 
Stores 
NCHIP Survey 
Availability of 
Misoprostol 
Availability of Misoprostol in maternity centers NCHIP Survey 
Stock Out Frequency of oxytocin stock outs NCHIP Survey 
 Frequency of MgSO4 stock outs NCHIP Survey 
Accessibilit
y 
 
Home Birth 
Misoprostol piloted for home birth  
 
NCHIP Survey 
 Misoprostol at home birth scaling up 
 
NCHIP Survey 
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 ANC attendance Antenatal care or skilled birth attendance) 
 
NCHIP Survey 
 Affordabilit
y 
Cost of Medicines Medicine is free of Charge to patients in health 
facility 
NCHIP Survey 
   Population covered by a public health service or 
public health insurance or social health 
insurance, or other sickness funds of total 
population) 
WHO 
pharmaceutical 
country profile 
data 
 
 
